<html lang="en" class="pb-page js" data-request-id="94d6d4f893d13289-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6d4f893d13289-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/XPgc7hdzTXK2iW9cI8V4_v4rUdCJfC2kdB3Io8e9HhmgnXXB97cNZRTNkGHwUA_wzH5MZvBkgQK8BIpYjr6B-g=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6d4f893d13289-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.05831808790137494"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Viral Infections|Vaccines|Coronavirus">
<meta name="Specialties" content="Infectious Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2202261","title":"Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults","category":"Research","type":"Original Article","topics":"Viral Infections|Vaccines|Coronavirus","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-06-02T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Vaccines|Coronavirus\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2202261","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6d4f893d13289-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults"><meta name="dc.Creator" content="Lianpan Dai"><meta name="dc.Creator" content="Lidong Gao"><meta name="dc.Creator" content="Lifeng Tao"><meta name="dc.Creator" content="Sri R. Hadinegoro"><meta name="dc.Creator" content="Musabaev Erkin"><meta name="dc.Creator" content="Zhifang Ying"><meta name="dc.Creator" content="Peng He"><meta name="dc.Creator" content="Rodman T. Girsang"><meta name="dc.Creator" content="Hugo Vergara"><meta name="dc.Creator" content="Javed Akram"><meta name="dc.Creator" content="Hindra I. Satari"><meta name="dc.Creator" content="Tanwir Khaliq"><meta name="dc.Creator" content="Ume Sughra"><meta name="dc.Creator" content="Ana P. Celi"><meta name="dc.Creator" content="Fangjun Li"><meta name="dc.Creator" content="Yan Li"><meta name="dc.Creator" content="Zhiwei Jiang"><meta name="dc.Creator" content="Dilbar Dalimova"><meta name="dc.Creator" content="Jaloliddin Tuychiev"><meta name="dc.Creator" content="Shahlo Turdikulova"><meta name="dc.Creator" content="Aamer Ikram"><meta name="dc.Creator" content="Nancy Flores Lastra"><meta name="dc.Creator" content="Fan Ding"><meta name="dc.Creator" content="Mahendra Suhardono"><meta name="dc.Creator" content="Eddy Fadlyana"><meta name="dc.Creator" content="Jinghua Yan"><meta name="dc.Creator" content="Zhongyu Hu"><meta name="dc.Creator" content="Changgui Li"><meta name="dc.Creator" content="Ibrokhim Y. Abdurakhmonov"><meta name="dc.Creator" content="George F. Gao"><meta name="dc.Description" content="The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with..."><meta name="Description" content="The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-06-02"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2202261"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202206023862207"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2201300"><meta name="dc.Relation" content="10.1056/NEJMe2204695"><meta name="dc.Relation" content="YXQYoa2202261"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2202261">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2202261">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2202261">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults | NEJM">
        <meta property="og:title" content="Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2202261">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/afe6bc88-4dd6-402a-bd8c-2c2b4c01a8d6/nejmoa2202261_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/afe6bc88-4dd6-402a-bd8c-2c2b4c01a8d6/nejmoa2202261_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of
severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant,
was shown to be safe, with...">
        <meta name="twitter:description" content="The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of
severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant,
was shown to be safe, with...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2990">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2202261">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2202261">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;issue:issue:doi\:10.1056/nejm_2022.386.issue-22;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms;article:article:doi\:10.1056/NEJMoa2202261">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2202261" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2202261" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2202261" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2202261" class="inputDoi"><input type="hidden" value="L. Dai and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:2097-2111" class="inputCitation"><input type="hidden" value="05-04-2022" class="inputEPubDate"><input type="hidden" value="June 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6d4f893d13289-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Lianpan</span> <span property="familyName">Dai</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lidong</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">M.S.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3869-615X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-3869-615X</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lifeng</span> <span property="familyName">Tao</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sri R.</span> <span property="familyName">Hadinegoro</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Musabaev</span> <span property="familyName">Erkin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zhifang</span> <span property="familyName">Ying</span>, <span property="honorificSuffix">B.A.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peng</span> <span property="familyName">He</span>, <span property="honorificSuffix">M.S.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+23</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rodman T.</span> <span property="familyName">Girsang</span>, <span property="honorificSuffix">M.Hlth.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hugo</span> <span property="familyName">Vergara</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Javed</span> <span property="familyName">Akram</span>, <span property="honorificSuffix">F.R.C.P.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hindra I.</span> <span property="familyName">Satari</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tanwir</span> <span property="familyName">Khaliq</span>, <span property="honorificSuffix">F.C.P.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ume</span> <span property="familyName">Sughra</span>, <span property="honorificSuffix">F.R.C.P.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ana P.</span> <span property="familyName">Celi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fangjun</span> <span property="familyName">Li</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yan</span> <span property="familyName">Li</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zhiwei</span> <span property="familyName">Jiang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dilbar</span> <span property="familyName">Dalimova</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jaloliddin</span> <span property="familyName">Tuychiev</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shahlo</span> <span property="familyName">Turdikulova</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Aamer</span> <span property="familyName">Ikram</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nancy</span> <span property="familyName">Flores Lastra</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fan</span> <span property="familyName">Ding</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mahendra</span> <span property="familyName">Suhardono</span>, <span property="honorificSuffix">M.M.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eddy</span> <span property="familyName">Fadlyana</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jinghua</span> <span property="familyName">Yan</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zhongyu</span> <span property="familyName">Hu</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Changgui</span> <span property="familyName">Li</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ibrokhim Y.</span> <span property="familyName">Abdurakhmonov</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">George F.</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">D.Phil.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3869-615X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-3869-615X</a></span></span>, for <span property="author" typeof="Person" role="listitem">the ZF2001 Global Trial Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-23</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">May 4, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">2097</span>-<span property="pageEnd">2111</span></div><div class="doi">DOI: 10.1056/NEJMoa2202261</div><div class="core-enumeration"><a href="/toc/nejm/386/22"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">22</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DLianpan%2BDai%252C%2BLidong%2BGao%252C%2BLifeng%2BTao%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa2202261%26title%3DEfficacy%2Band%2BSafety%2Bof%2Bthe%2BRBD-Dimer%25E2%2580%2593Based%2BCovid-19%2BVaccine%2BZF2001%2Bin%2BAdults%26publicationDate%3D06%252F02%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2202261" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DLianpan%2BDai%252C%2BLidong%2BGao%252C%2BLifeng%2BTao%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa2202261%26title%3DEfficacy%2Band%2BSafety%2Bof%2Bthe%2BRBD-Dimer%25E2%2580%2593Based%2BCovid-19%2BVaccine%2BZF2001%2Bin%2BAdults%26publicationDate%3D06%252F02%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/4e417a5b-190f-4cb0-a69b-658278e7a6d1/nejmoa2202261.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2202261.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2202261" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2202261" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2202261.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with an acceptable side-effect profile, and immunogenic in adults in phase 1 and 2 clinical trials.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to investigate the efficacy and confirm the safety of ZF2001. The trial was performed at 31 clinical centers across Uzbekistan, Indonesia, Pakistan, and Ecuador; an additional center in China was included in the safety analysis only. Adult participants (≥18 years of age) were randomly assigned in a 1:1 ratio to receive a total of three 25-μg doses (30 days apart) of ZF2001 or placebo. The primary end point was the occurrence of symptomatic coronavirus disease 2019 (Covid-19), as confirmed on polymerase-chain-reaction assay, at least 7 days after receipt of the third dose. A key secondary efficacy end point was the occurrence of severe-to-critical Covid-19 (including Covid-19–related death) at least 7 days after receipt of the third dose.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Between December 12, 2020, and December 15, 2021, a total of 28,873 participants received at least one dose of ZF2001 or placebo and were included in the safety analysis; 25,193 participants who had completed the three-dose regimen, for whom there were approximately 6 months of follow-up data, were included in the updated primary efficacy analysis that was conducted at the second data cutoff date of December 15, 2021. In the updated analysis, primary end-point cases were reported in 158 of 12,625 participants in the ZF2001 group and in 580 of 12,568 participants in the placebo group, for a vaccine efficacy of 75.7% (95% confidence interval [CI], 71.0 to 79.8). Severe-to-critical Covid-19 occurred in 6 participants in the ZF2001 group and in 43 in the placebo group, for a vaccine efficacy of 87.6% (95% CI, 70.6 to 95.7); Covid-19–related death occurred in 2 and 12 participants, respectively, for a vaccine efficacy of 86.5% (95% CI, 38.9 to 98.5). The incidence of adverse events and serious adverse events was balanced in the two groups, and there were no vaccine-related deaths. Most adverse reactions (98.5%) were of grade 1 or 2.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In a large cohort of adults, the ZF2001 vaccine was shown to be safe and effective against symptomatic and severe-to-critical Covid-19 for at least 6 months after full vaccination. (Funded by the National Science and Technology Major Project and others; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04646590" target="_blank">NCT04646590</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Control of the coronavirus disease 2019 (Covid-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global priority.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Vaccination, with a supply of multiple vaccines based on different platforms, is the cornerstone of pandemic control.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3" id="body-ref-r3-1" href-manipulated="true">2,3</a></sup> The results of clinical studies of the efficacy of Covid-19 vaccines based on different platforms have been reported,<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6 r7 r8 r9 r10 r11 r12 r13 r14 r15" id="body-ref-r15-1" href-manipulated="true">4-15</a></sup> and those that use messenger RNA (mRNA) or adjuvanted recombinant protein were shown to have an efficacy of 90 to 96%.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r13" id="body-ref-r13-2" href-manipulated="true">8,9,13</a></sup> These vaccines target either the whole virus or the spike protein. Although the receptor-binding domain (RBD) has been widely used as the Covid-19 vaccine target (four vaccines have been approved for emergency use and several are in late stages of clinical trials<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r16" id="body-ref-r16-1" href-manipulated="true">3,16</a></sup>), data regarding the efficacy of RBD-based vaccines are lacking.</div><div role="paragraph">Currently, B.1.617.2 (delta) and B.1.1.529 (omicron), the highly transmissible SARS-CoV-2 variants of concern, have brought new waves of infection worldwide and have accounted for breakthrough infections owing to their reduced sensitivity to the currently available vaccines.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> Although vaccine effectiveness has been reported in real-world studies,<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> clinical efficacy against the prevalent delta variant of concern has been reported for only two vaccines in two randomized, controlled phase 3 trials. In one trial, the BBV152 vaccine (Bharat Biotech International) was shown to have an efficacy of 65.2%,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-2" href-manipulated="true" aria-label="Reference 5">5</a></sup> and in another, the SCB-2019 vaccine was shown to have an efficacy of 78.7%.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15-2" href-manipulated="true" aria-label="Reference 15">15</a></sup></div><div role="paragraph">We developed a protein subunit Covid-19 vaccine, ZF2001, using the tandem-repeat dimeric RBD of the SARS-CoV-2 spike protein (from the original Wuhan-Hu-1 strain) as the antigen.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> The antigen protein is produced in Chinese hamster ovary cells and then adjuvanted with aluminum hydroxide to produce the vaccine. ZF2001 requires less stringent cold-chain transport and storage, a factor that facilitates its availability in the global supply. Preclinical studies of ZF2001 have shown the immunogenicity and protective efficacy of the vaccine in rodents and macaques.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> The phase 1 and 2 clinical trials showed that the ZF2001 vaccine is safe, with an acceptable side-effect profile, and immunogenic in humans, and a three-dose regimen was selected for use in a phase 3 trial.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-1" href-manipulated="true" aria-label="Reference 21">21</a></sup> In serum samples, the majority of vaccine-elicited neutralizing activities against the B.1.351 (beta) variant of concern<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> and pseudovirus expressing a panel of spikes from variants of concern and variants of interest, including B.1.1.7 (alpha), beta, delta, B.1.617.1 (kappa), and omicron,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24" id="body-ref-r24-1" href-manipulated="true">23,24</a></sup> were shown to be preserved. ZF2001 has been approved in China, Uzbekistan, Indonesia, and Colombia.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-3" href-manipulated="true" aria-label="Reference 3">3</a></sup> Here, we report the results of a multinational, randomized, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of ZF2001 in adults 18 years of age or older during a period when the delta variant was prevalent.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">The trial was conducted at 31 centers in Uzbekistan, Indonesia, Pakistan, and Ecuador (see the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). An additional center in China was included only in the safety evaluation because of the difficulty in efficacy evaluation posed by the dynamic zero–Covid-19 strategy used in China. All the participants provided written informed consent. The trial <a href="#ap1">protocol</a> (available at NEJM.org), the written informed consent form, and other information related to participants were approved by the clinical research ethics board of the Hunan Provincial Center for Disease Control and Prevention (China) and the corresponding ethics committees in the other four countries. The trial was conducted according to the principles of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and the International Ethical Guidelines on Biomedical Research Involving Human Subjects.</div><div role="paragraph">Cases of Covid-19 meeting the definition of the primary end point (i.e., the occurrence of symptomatic Covid-19, as confirmed on polymerase-chain-reaction [PCR] assay, at least 7 days after the third dose [hereafter, primary end-point cases]) and the classification of disease severity were verified by an independent end-point adjudication committee. Safety oversight was performed by an independent data safety and monitoring board.</div><div role="paragraph">The conduct of the trial was overseen by Anhui Zhifei Longcom Biopharmaceutical (Zhifei), which manufactured the investigational products and used contract clinical research organizations to coordinate interactions between regulatory authorities and staff at the clinical sites regarding operations. Zhifei and collaborators designed the trial. The trial-site investigators collected the data, and representatives from Beijing Keytech Statistical Technology analyzed the data. The first author wrote the initial draft of the manuscript with input from the other authors. The data were available to all the authors, who vouch for the accuracy and completeness of the data and the analysis and for adherence of the trial to the protocol. All the authors had final responsibility for the decision to submit the manuscript for publication. No confidentiality agreements were in place between Zhifei and the authors or affiliated institutions.</div></section><section id="sec-1-2"><h3>Trial Participants and Procedures</h3><div role="paragraph">Volunteers 18 years of age or older who had provided written informed consent underwent screening for eligibility. Key exclusion criteria were a history of Covid-19, positive tests for SARS-CoV-2 exposure or vaccination, and a history of congenital or acquired immune deficiency or autoimmune disease. Full details regarding the inclusion and exclusion criteria are provided in the trial <a href="#ap1">protocol</a>.</div><div role="paragraph">Details of the trial procedures are provided in the trial <a href="#ap1">protocol</a>. Briefly, the participants were randomly assigned in a 1:1 ratio to receive three intramuscular injections in the deltoid region, administered 30 days apart, of the ZF2001 vaccine (with each dose containing 25 μg of RBD-dimer protein with 0.25 mg of aluminum hydroxide in 0.5 ml of buffer) or placebo (with each dose containing 0.25 mg of aluminum hydroxide in 0.5 ml of buffer) (Table S2). Randomization was stratified according to trial center and age (18 to 59 years or ≥60 years) and was performed with the use of an interactive Web-response system (version 5.0, Shanhu Health). The statisticians who conducted randomization were not involved in other work relevant to this clinical trial. The trial participants, field investigators, and nurses who administrated the vaccine or placebo were unaware of the trial-group assignments during the trial.</div></section><section id="sec-1-3"><h3>Efficacy Assessments</h3><div role="paragraph">The primary efficacy end point was real-time PCR–confirmed symptomatic Covid-19 occurring at least 7 days after the third dose. Key secondary efficacy end points were severe-to-critical Covid-19 (including Covid-19–related death) occurring at least 7 days after the third dose and Covid-19 of any severity occurring at least 7 days after the third dose in subgroups defined according to age (18 to 59 years vs. ≥60 years). A key exploratory objective was the determination of vaccine efficacy against SARS-CoV-2 variants.</div><div role="paragraph">Participants with Covid-19 were monitored by the investigators through both symptom-driven passive surveillance and active follow-up visits (every 3 to 7 days) (see the Supplementary Methods section in the <a href="#ap2">Supplementary Appendix</a>). After the first dose of vaccine or placebo, a participant with any symptom of suspected Covid-19 would contact or be contacted by the investigators by telephone, text message, or email or be interviewed face -to-face. Details of the diagnostic criteria and definition of Covid-19 cases are provided in the trial <a href="#ap2">protocol</a>. If the case was confirmed by the investigators, examinations would be performed for further verification, including real-time PCR assay for SARS-CoV-2 RNA in nasopharyngeal swab samples and measurements of the respiratory rate, oxygen saturation, and oxygenation index. Samples were obtained again for testing within 24 to 48 hours after the PCR assay for case confirmation. At least one positive real-time PCR assay was required for the adjudicated cases. The <i>S</i> gene of SARS-CoV-2 in the positive samples was genotyped (see the Supplementary Methods section). Data regarding all suspected Covid-19 cases that were positive on real-time PCR assay, as well as the severity of disease, were reviewed and confirmed by the end-point adjudication committee.</div></section><section id="sec-1-4"><h3>Safety Assessments</h3><div role="paragraph">Incident adverse events occurring within 30 minutes after each inoculation were recorded in the observation room. Adverse events (both solicited and unsolicited) occurring at 0 to 7 days after each inoculation were recorded by the participants on diary cards, which were collected by the investigators at the trial visits. Unsolicited adverse events occurring 8 to 30 days after each inoculation were recorded by the participants on contact cards. Serious adverse events occurring from the time after the first inoculation through 12 months after receipt of the third dose were documented by the investigators during telephone calls; the monitoring of serious adverse events was ongoing at the time of publication.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">In accordance with the guidelines of the World Health Organization (WHO) regarding vaccine efficacy,<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26" id="body-ref-r26" href-manipulated="true">25,26</a></sup> we aimed to detect a target vaccine efficacy of 60%, with the lower boundary of the 95% confidence interval of more than 30%. Assuming that the incidence of Covid-19 of any severity would be 1% during the trial period, we estimated that a sample of 22,144 participants (11,072 in each group) and 156 Covid-19 cases of any severity (as calculated by means of the exact conditional method according to the large-sample hypothesis of Poisson distribution of Chan and Bohidar<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup>) would be required to provide the trial with 90% power to detect the target vaccine efficacy at a two-sided significance level of 5%. Therefore, considering the number of patients who would drop out, be involved in a protocol violation, or not adhere to the trial regimen, we planned to randomly assign 14,000 participants to each trial group.</div><div role="paragraph">Two interim analyses were planned, with the first to be conducted when at least one third of the estimated 156 Covid-19 cases of any severity had been reported and the second to be conducted when at least two thirds of the cases had been reported. The overall family-wise type I error was controlled at a two-sided significance level of 5% with the use of an O’Brien–Fleming alpha-spending function.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup></div><div role="paragraph">A Poisson regression model was used to calculate the vaccine efficacy and the 95% confidence interval on the basis of the number of cases per person-year. Although two interim analyses were planned in this trial, more than 156 Covid-19 cases were reported and confirmed by the end-point adjudication committee as of June 30, 2021. The final analysis was conducted directly without any interim evaluation at the data cutoff date of June 30, 2021. Thus, the significance level of the test was not adjusted. An updated analysis with a second data cutoff date of December 15, 2021, was conducted 6 months after receipt of the third dose. Our hypothesis that the vaccine would provide better protection against Covid-19 of any severity than placebo at least 7 days after the third dose would be confirmed when the lower boundary of the 95% confidence interval for vaccine efficacy was more than 30%.</div><div role="paragraph">Analyses of vaccine efficacy beginning after the first dose included all the participants who had undergone randomization and received at least one dose of vaccine or placebo (the full analysis set), and analyses of vaccine efficacy beginning 7 days after the third dose (the primary efficacy analysis) included all the participants who completed the three-dose regimen of vaccine or placebo (the modified full analysis set). Participants who had received the incorrect trial regimen were included in the analysis according to their trial-group assignment on the basis of the intention-to-treat principle. The safety analysis set included all the participants who had undergone randomization and received at least one dose of vaccine or placebo; the participants were evaluated according to the trial regimen they had actually received. Additional exclusion criteria regarding the analysis populations are listed in Table S3 in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">Between December 12, 2020, and December 15, 2021, a total of 28,904 participants were enrolled and underwent randomization at 32 clinical centers across 5 countries (China, Uzbekistan, Indonesia, Pakistan, and Ecuador). The demographic and clinical characteristics of the participants were similar in the two trial groups and in the subgroups defined according to age, body-mass index, race, and the presence of coexisting medical conditions (<a href="#t1">Table 1</a>). Among these participants, 27,065 (93.6%) were 18 to 59 years of age, 1839 (6.4%) were 60 years of age or older, and 9383 (32.5%) were female. A total of 78.5% of the participants were Asian, and 17.7% were multiracial. More than 99.9% of the participants were negative for SARS-CoV-2 exposure or vaccination. At baseline, 13.2% of the participants had a coexisting medical condition.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t1.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/efad7c94-7163-4f5b-a15c-55247858575c/assets/images/large/nejmoa2202261_t1.jpg" height="2545" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Characteristic</th><th class="xxxx-borders">ZF2001<br>(N=14,453)<a href="#t1fn2" role="doc-noteref">†</a></th><th class="xxxx-borders">Placebo<br>(N=14,451)<a href="#t1fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">All Participants<br>(N=28,904)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">37.0±13.1</td><td class="xxxx-borders shading">36.7±13.1</td><td class="xxxx-borders shading">36.8±13.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">35.0 (18–92)</td><td class="xxxx-borders">35.0 (17–88)</td><td class="xxxx-borders">35.0 (17–92)</td></tr><tr data-type="row"><td class="xxxx-borders hanging14 shading">Distribution</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24" data-xml-align="left">18–59 yr — no. (%)</td><td class="xxxx-borders">13,534 (93.6)</td><td class="xxxx-borders">13,531 (93.6)</td><td class="xxxx-borders">27,065 (93.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34 shading" data-xml-align="left">Mean — yr</td><td class="xxxx-borders shading">35.0±11.0</td><td class="xxxx-borders shading">34.7±10.9</td><td class="xxxx-borders shading">34.8±10.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">34.0 (18–59)</td><td class="xxxx-borders">34.0 (17–59)</td><td class="xxxx-borders">34.0 (17–59)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24 shading" data-xml-align="left">≥60 yr</td><td class="xxxx-borders shading">919 (6.4)</td><td class="xxxx-borders shading">920 (6.4)</td><td class="xxxx-borders shading">1,839 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">66.2±5.6</td><td class="xxxx-borders">65.8±5.0</td><td class="xxxx-borders">66.0±5.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34 shading" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders shading">65.0 (60–92)</td><td class="xxxx-borders shading">65.0 (60–88)</td><td class="xxxx-borders shading">65.0 (60–92)</td></tr><tr data-type="row"><td class="xxxx-borders hanging04">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">9,766 (67.6)</td><td class="xxxx-borders shading">9,755 (67.5)</td><td class="xxxx-borders shading">19,521 (67.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Female</td><td class="xxxx-borders">4,687 (32.4)</td><td class="xxxx-borders">4,696 (32.5)</td><td class="xxxx-borders">9,383 (32.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging04 shading" data-xml-align="left">Body-mass index<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">25.53±4.7</td><td class="xxxx-borders shading">25.55±4.7</td><td class="xxxx-borders shading">25.54±4.7</td></tr><tr data-type="row"><td class="xxxx-borders hanging04">Race or ethnic group — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Ethnic Chinese</td><td class="xxxx-borders shading">503 (3.5)</td><td class="xxxx-borders shading">503 (3.5)</td><td class="xxxx-borders shading">1,006 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Asian but not ethnic Chinese</td><td class="xxxx-borders">11,251 (77.8)</td><td class="xxxx-borders">11,225 (77.7)</td><td class="xxxx-borders">22,476 (77.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Black or African or Caribbean</td><td class="xxxx-borders shading">5 (&lt;0.1)</td><td class="xxxx-borders shading">8 (&lt;0.1)</td><td class="xxxx-borders shading">13 (&lt;0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">White</td><td class="xxxx-borders">41 (0.3)</td><td class="xxxx-borders">59 (0.4)</td><td class="xxxx-borders">100 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Multiracial</td><td class="xxxx-borders shading">2,650 (18.3)</td><td class="xxxx-borders shading">2,655 (18.4)</td><td class="xxxx-borders shading">5,305 (18.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Other</td><td class="xxxx-borders">3 (&lt;0.1)</td><td class="xxxx-borders">1 (&lt;0.1)</td><td class="xxxx-borders">4 (&lt;0.1)</td></tr><tr data-type="row"><td class="xxxx-borders hanging04 shading">SARS-CoV-2 status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Positive for IgG, IgM, or antigen or had positive real-time PCR assay<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">3 (&lt;0.1)</td><td class="xxxx-borders">4 (&lt;0.1)</td><td class="xxxx-borders">7 (&lt;0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Negative for IgG, IgM, and antigen and had negative real-time PCR assay</td><td class="xxxx-borders shading">14,437 (99.9)</td><td class="xxxx-borders shading">14,429 (99.8)</td><td class="xxxx-borders shading">28,866 (99.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Data missing</td><td class="xxxx-borders">13 (&lt;0.1)</td><td class="xxxx-borders">18 (0.1)</td><td class="xxxx-borders">31 (0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging04 shading" data-xml-align="left">Any coexisting medical condition — no. (%)<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">1,904 (13.2)</td><td class="xxxx-borders shading">1,925 (13.3)</td><td class="xxxx-borders shading">3,829 (13.2)</td></tr><tr data-type="row"><td class="xxxx-borders hanging14">Distribution according to age group</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24 shading" data-xml-align="left">18–59 yr</td><td class="xxxx-borders shading">1,601 (11.1)</td><td class="xxxx-borders shading">1,617 (11.2)</td><td class="xxxx-borders shading">3,218 (11.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24" data-xml-align="left">≥60 yr</td><td class="xxxx-borders">303 (2.1)</td><td class="xxxx-borders">308 (2.1)</td><td class="xxxx-borders">611 (2.1)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Intention-to-Treat Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. PCR denotes polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Among the participants who had been randomly assigned to receive ZF2001, placebo was incorrectly administered to 8 at the first dose, 9 at the second dose, and 4 at the third dose. These participants were included in the protocol violation report.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Among the participants who had been randomly assigned to receive placebo, ZF2001 was incorrectly administered to 4 at the first dose, 3 at the second dose, and 3 at the third dose. These participants were included in the protocol violation report.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Race or ethnic group was reported by the participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Seven participants who were positive for IgG or IgM antibodies or SARS-CoV-2 antigen or had a positive real-time PCR assay at baseline were recruited by the site investigators in error. These participants were included in the protocol violation report.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Coexisting medical conditions were diseases that had started before the first dose and ended after the first dose or persisted during the trial. Coexisting conditions were classified according to the <i>Medical Dictionary for Regulatory Activities</i>, version 24.0.</div></div></div></figcaption></figure></div><div role="paragraph">At the first data cutoff date (June 30, 2021), a total of 28,470 participants had received at least one dose of vaccine or placebo, and 14,681 were included in the modified full analysis set for efficacy (Fig. S1 and Tables S3 and S6). At the second data cutoff date (December 15, 2021), a total of 28,873 participants had received at least one dose of ZF2001 or placebo and were included in the safety analysis set. The modified full analysis set for efficacy included 25,193 participants (<a href="#f1">Figure 1</a> and Table S7).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f1.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/afe6bc88-4dd6-402a-bd8c-2c2b4c01a8d6/assets/images/large/nejmoa2202261_f1.jpg" height="2990" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, Follow-up, and Analyses Performed up to the Second Data Cutoff Date of December 15, 2021.</div><div class="notes"><div role="doc-footnote">Eight participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group in the safety analysis. Covid-19 denotes coronavirus disease 2019.</div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy after Short-Term Follow-up</h3><div role="paragraph">At the first data cutoff date, 663 Covid-19 cases were confirmed on real-time PCR assay after the first dose; 224 of these cases had an onset at least 7 days after the third dose and were analyzed as primary end-point cases. The mean (±SD) duration of follow-up, starting 7 days after the third dose, was 50.4±37.1 days in the ZF2001 group and 50.6±37.1 days in the placebo group. A total of 36 cases occurred among 7359 participants in the ZF2001 group, and 188 cases occurred among 7322 participants in the placebo group. These results yielded a vaccine efficacy of 81.4% (95% confidence interval [CI], 73.3 to 87.3) (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/28baa0e7-0af5-4182-9d5b-bdd50505a150/assets/images/large/nejmoa2202261_t2.jpg" height="2832" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Efficacy Analysis</th><th class="txxx-borders" colspan="4"><span>At First Data Cutoff: June 30, 2021</span></th><th class="txxr-borders" colspan="4"><span>At Second Data Cutoff: Dec. 15, 2021</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total Cases</th><th class="xxxx-borders">ZF2001</th><th class="xxxx-borders">Placebo</th><th class="xxxx-borders">Vaccine Efficacy<br>(95% CI)</th><th class="xxxx-borders">Total Cases</th><th class="xxxx-borders">ZF2001</th><th class="xxxx-borders">Placebo</th><th class="xxxr-borders">Vaccine Efficacy<br>(95% CI)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no.</th><th class="xxxx-borders" colspan="2"><span>no. of cases/no. at risk</span></th><th class="xxxx-borders">%</th><th class="xxxx-borders">no.</th><th class="xxxx-borders" colspan="2"><span>no. of cases/no. at risk</span></th><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Analyses in the modified full analysis set</b><a href="#t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Primary end point: symptomatic Covid-19 occurring ≥7 days after the third dose</td><td class="xxxx-borders">224</td><td class="xxxx-borders">36/7359</td><td class="xxxx-borders">188/7322</td><td class="xxxx-borders">81.4 (73.3 to 87.3)</td><td class="xxxx-borders">738</td><td class="xxxx-borders">158/12,625</td><td class="xxxx-borders">580/12,568</td><td class="xxxr-borders">75.7 (71.0 to 79.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Secondary end point: severe-to-critical Covid-19 occurring ≥7 days after the third dose</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">1/7359</td><td class="xxxx-borders shading">13/7322</td><td class="xxxx-borders shading">92.9 (52.4 to 99.8)</td><td class="xxxx-borders shading">49</td><td class="xxxx-borders shading">6/12,656</td><td class="xxxx-borders shading">43/12,568</td><td class="xxxr-borders shading">87.6 (70.6 to 95.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Secondary end-point component: Covid-19–related death occurring ≥7 days after the third dose</td><td class="xxxx-borders">5</td><td class="xxxx-borders">0/7359</td><td class="xxxx-borders">5/7322</td><td class="xxxx-borders">100 (−8.4 to 100)</td><td class="xxxx-borders">14</td><td class="xxxx-borders">2/12,656</td><td class="xxxx-borders">12/12,568</td><td class="xxxr-borders">86.5 (38.9 to 98.5)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><b>Subgroup analyses in the modified full analysis set</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders">Analysis according to age</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">18–59 yr</td><td class="xxxx-borders shading">216</td><td class="xxxx-borders shading">35/7153</td><td class="xxxx-borders shading">181/7111</td><td class="xxxx-borders shading">81.2 (72.8 to 87.3)</td><td class="xxxx-borders shading">710</td><td class="xxxx-borders shading">150/11,921</td><td class="xxxx-borders shading">560/11,846</td><td class="xxxr-borders shading">76.0 (71.2 to 80.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥60 yr</td><td class="xxxx-borders">8</td><td class="xxxx-borders">1/206</td><td class="xxxx-borders">7/211</td><td class="xxxx-borders">87.6 (2.5 to 99.7)</td><td class="xxxx-borders">28</td><td class="xxxx-borders">8/704</td><td class="xxxx-borders">20/722</td><td class="xxxr-borders">67.6 (21.9 to 87.8)</td></tr><tr data-type="row"><td class="xxlx-borders shading">Analysis according to country<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Uzbekistan</td><td class="xxxx-borders">53</td><td class="xxxx-borders">7/3185</td><td class="xxxx-borders">46/3180</td><td class="xxxx-borders">84.8 (66.2 to 94.2)</td><td class="xxxx-borders">191</td><td class="xxxx-borders">35/3226</td><td class="xxxx-borders">156/3221</td><td class="xxxr-borders">80.2 (71.3 to 86.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Indonesia</td><td class="xxxx-borders shading">159</td><td class="xxxx-borders shading">28/1908</td><td class="xxxx-borders shading">131/1895</td><td class="xxxx-borders shading">79.4 (68.9 to 86.9)</td><td class="xxxx-borders shading">352</td><td class="xxxx-borders shading">77/1927</td><td class="xxxx-borders shading">275/1902</td><td class="xxxr-borders shading">76.0 (68.9 to 81.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Ecuador</td><td class="xxxx-borders">12</td><td class="xxxx-borders">1/1323</td><td class="xxxx-borders">11/1293</td><td class="xxxx-borders">91.2 (39.5 to 99.8)</td><td class="xxxx-borders">130</td><td class="xxxx-borders">33/2280</td><td class="xxxx-borders">97/2249</td><td class="xxxr-borders">67.6 (51.4 to 78.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pakistan</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0/943</td><td class="xxxx-borders shading">0/954</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">13/5192</td><td class="xxxx-borders shading">52/5196</td><td class="xxxr-borders shading">75.1 (53.7 to 87.6)</td></tr><tr data-type="row"><td class="xxlx-borders">Analysis according to race</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">211</td><td class="xxxx-borders shading">35/5997</td><td class="xxxx-borders shading">176/5964</td><td class="xxxx-borders shading">80.7 (72.1 to 87.0)</td><td class="xxxx-borders shading">601</td><td class="xxxx-borders shading">124/10,303</td><td class="xxxx-borders shading">477/10,252</td><td class="xxxr-borders shading">77.2 (72.2 to 81.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other race</td><td class="xxxx-borders">13</td><td class="xxxx-borders">1/1362</td><td class="xxxx-borders">12/1358</td><td class="xxxx-borders">91.7 (43.4 to 99.8)</td><td class="xxxx-borders">137</td><td class="xxxx-borders">34/2322</td><td class="xxxx-borders">103/2316</td><td class="xxxr-borders">68.2 (52.8 to 79.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Analysis according to coexisting conditions that were risk factors for severe Covid-19</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cardiovascular disease</td><td class="xxxx-borders">12</td><td class="xxxx-borders">1/203</td><td class="xxxx-borders">11/242</td><td class="xxxx-borders">93.1 (45.4 to 99.9)</td><td class="xxxx-borders">38</td><td class="xxxx-borders">11/401</td><td class="xxxx-borders">27/454</td><td class="xxxr-borders">64.0 (20.2 to 84.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diabetes</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">1/88</td><td class="xxxx-borders shading">4/95</td><td class="xxxx-borders shading">31.7 (−1264.8 to 98.9)</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">5/279</td><td class="xxxx-borders shading">12/299</td><td class="xxxr-borders shading">55.4 (−60.4 to 90.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Chronic lung disease</td><td class="xxxx-borders">3</td><td class="xxxx-borders">1/42</td><td class="xxxx-borders">2/27</td><td class="xxxx-borders">74.0 (−435.3 to 99.6)</td><td class="xxxx-borders">7</td><td class="xxxx-borders">2/54</td><td class="xxxx-borders">5/43</td><td class="xxxr-borders">86.7 (−13.9 to 99.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Severe obesity</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0/8</td><td class="xxxx-borders shading">1/11</td><td class="xxxx-borders shading">100 (−3275.7 to 100)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0/9</td><td class="xxxx-borders shading">1/14</td><td class="xxxr-borders shading">100 (−4353.8 to 100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any of the above</td><td class="xxxx-borders">19</td><td class="xxxx-borders">3/308</td><td class="xxxx-borders">16/344</td><td class="xxxx-borders">84.4 (41.9 to 97.2)</td><td class="xxxx-borders">58</td><td class="xxxx-borders">18/661</td><td class="xxxx-borders">40/716</td><td class="xxxr-borders">61.6 (29.5 to 79.9)</td></tr><tr data-type="row"><td class="xxlx-borders shading">Analysis according to SARS-CoV-2 variant<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">B.1.617.2, AY.4, AY.6, or AY.12 (delta)</td><td class="xxxx-borders">130</td><td class="xxxx-borders">21/7359</td><td class="xxxx-borders">109/7322</td><td class="xxxx-borders">81.4 (70.1 to 88.9)</td><td class="xxxx-borders">454</td><td class="xxxx-borders">96/12,625</td><td class="xxxx-borders">358/12,568</td><td class="xxxr-borders">76.1 (70.0 to 81.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">B.1.1.7 (alpha)</td><td class="xxxx-borders shading">29</td><td class="xxxx-borders shading">2/7359</td><td class="xxxx-borders shading">27/7322</td><td class="xxxx-borders shading">92.7 (70.9 to 99.2)</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">4/12,625</td><td class="xxxx-borders shading">31/12,568</td><td class="xxxr-borders shading">88.3 (66.8 to 97.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">B.1.617.1 (kappa) or B.1.617.3</td><td class="xxxx-borders">15</td><td class="xxxx-borders">2/7359</td><td class="xxxx-borders">13/7322</td><td class="xxxx-borders">84.8 (32.9 to 98.3)</td><td class="xxxx-borders">68</td><td class="xxxx-borders">15/12,625</td><td class="xxxx-borders">53/12,568</td><td class="xxxr-borders">75.2 (55.3 to 87.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other variants or not identified<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">50</td><td class="xxxx-borders shading">11/7359</td><td class="xxxx-borders shading">38/7322</td><td class="xxxx-borders shading">71.3 (42.7 to 86.8)</td><td class="xxxx-borders shading">181</td><td class="xxxx-borders shading">43/12,625</td><td class="xxxx-borders shading">138/12,568</td><td class="xxxr-borders shading">71.9 (60.1 to 80.5)</td></tr><tr data-type="row"><td class="xxlx-borders"><b>Analyses in the full analysis set</b><a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Symptomatic Covid-19 since the first dose</td><td class="xxxx-borders shading">663</td><td class="xxxx-borders shading">249/13,669</td><td class="xxxx-borders shading">414/13,664</td><td class="xxxx-borders shading">40.2 (29.9 to 49.1)</td><td class="xxxx-borders shading">1255</td><td class="xxxx-borders shading">405/13,909</td><td class="xxxx-borders shading">850/13,899</td><td class="xxxr-borders shading">55.4 (49.7 to 60.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Severe-to-critical Covid-19 since the first dose</td><td class="xxxx-borders">59</td><td class="xxxx-borders">26/13,669</td><td class="xxxx-borders">33/13,664</td><td class="xxxx-borders">21.6 (−35.1 to 55.0)</td><td class="xxxx-borders">101</td><td class="xxxx-borders">36/13,909</td><td class="xxxx-borders">65/13,899</td><td class="xxxr-borders">47.4 (19.8 to 66.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders shading" data-xml-align="left">Covid-19–related death since the first dose</td><td class="xbxx-borders shading">6</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">6/13,664</td><td class="xbxx-borders shading">100 (15.2 to 100)</td><td class="xbxx-borders shading">18</td><td class="xbxx-borders shading">4/13,909</td><td class="xbxx-borders shading">14/13,898</td><td class="xbxr-borders shading">75.5 (21.5 to 94.1)</td></tr></tbody></table></div><figcaption><div class="caption">Vaccine Efficacy of ZF2001 against Covid-19 According to Analysis Groups.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The modified full analysis set for efficacy included all the participants who had undergone randomization and completed the three-dose regimen (additional exclusion criteria are listed in Table S3 in the <a href="#ap2">Supplementary Appendix</a>). Participants who had received the incorrect trial regimen were included in the analysis according to their trial-group assignment on the basis of the intention-to-treat principle. Covid-19 denotes coronavirus disease 2019, and NA not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Lot 1 vaccine was used in the Uzbekistan cohort, and lot 2 vaccine was used in the other countries.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Vaccine efficacy against each severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant was determined on the basis of symptomatic cases in the modified full analysis set for efficacy that were confirmed on real-time PCR assay and had SARS-CoV-2 genotyped with nasopharyngeal swabs.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Nasopharyngeal swabs with a cycle threshold value of 30 or more were not genotyped. We were able to retrieve sequences or genotypes from 185 case samples in the short-term follow-up and 626 case samples in the long-term follow-up. Shown are the efficacies against three major variants. The other 11 confirmed SARS-CoV-2 variants identified in the short-term follow-up and 69 in the long-term follow-up are shown in Table S14.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">The full analysis set for efficacy included all the participants who had undergone randomization and received at least one dose of vaccine or placebo. The full analysis set was used to evaluate protective efficacy after the first dose. The end-point cases were counted since the receipt of the first dose of vaccine or placebo. The current analysis did not include data from 7 participants who had a positive test for IgG or IgM antibodies or SARS-CoV-2 antigen or had a positive real-time PCR assay at baseline and those who had not yet completed at least one case-surveillance follow-up visit (121 patients at the first data cutoff date and 27 at the second data cutoff date).</div></div></div></figcaption></figure></div><div role="paragraph">The cumulative incidence of Covid-19 events over time among the participants in the ZF2001 group and those in the placebo group diverged immediately after the beginning of follow-up for the primary end-point analysis, a result indicating the start of protection (<a href="#f2">Figure 2A</a>). Among the participants who received at least one dose of vaccine or placebo in the full analysis set for efficacy, a late onset of protection and low vaccine efficacy were observed before the third dose (<a href="#f2">Figure 2C</a> and Tables S10 and S11).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f2.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/60565818-8d32-42d9-970e-ad174ee0ba13/assets/images/large/nejmoa2202261_f2.jpg" height="1932" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Plots of the Cumulative Incidence of Symptomatic Covid-19 in the Trial Groups.</div><div class="notes"><div role="doc-footnote">The cumulative incidence of symptomatic Covid-19, as confirmed on real-time polymerase-chain-reaction (PCR) assay, with an onset of at least 7 days after the third dose of ZF2001 or placebo (the primary end point) in the modified full analysis set for efficacy is shown at the first data cutoff date of June 30, 2021 (Panel A) and at the second data cutoff date of December 15, 2021 (Panel B). The cumulative incidence of real-time PCR–confirmed symptomatic Covid-19, with an onset after the first dose of ZF2001 or placebo, in the full analysis set for efficacy is shown at the first data cutoff date of June 30, 2021 (Panel C) and at the second data cutoff date of December 15, 2021 (Panel D). In each panel, the inset shows the same data on an enlarged y axis.</div></div></figcaption></figure></div><div role="paragraph">A total of 14 cases met the criteria for severe-to-critical Covid-19 in the modified full analysis set for efficacy. One case occurred in the ZF2001 group, and 13 occurred in the placebo group. These results yielded a vaccine efficacy of 92.9% (95% CI, 52.4 to 99.8). A total of five Covid-19–related deaths occurred — all in the placebo group (<a href="#t2">Table 2</a>). Among the participants with coexisting medical conditions that were risk factors for severe Covid-19, vaccine efficacy was 84.4% (95% CI, 41.8 to 97.2). Among the participants 18 to 59 years of age, vaccine efficacy was 81.2% (95% CI, 72.8 to 87.3), and among those 60 years of age or older, vaccine efficacy was 87.6% (95% CI, 2.5 to 99.7). Two lots of ZF2001 vaccine were used in this trial. Lot 1 was used in the Uzbekistan cohort, and lot 2 was used in the other countries. Both lots had an efficacy of more than 80%.</div><div role="paragraph">In a post hoc exploratory analysis of the primary end-point cases, 185 SARS-CoV-2–positive swab samples yielded genotyping results, all of which showed variants. The three major variants were the delta (B.1.617.2, AY.4, AY.6, and AY.12) variant of concern (130 cases), the alpha (B.1.1.7) variant of concern (29 cases), and the kappa (B.1.617.1) variant of interest plus the B.1.617.3 variant (15 cases). Vaccine efficacy was 81.4% (95% CI, 70.1 to 88.9) against the delta variant, 92.7% (95% CI, 70.9 to 99.2) against the alpha variant, and 84.8% (95% CI, 32.9 to 98.3) against the kappa variant plus the B.1.617.3 variant (<a href="#t2">Table 2</a>).</div></section><section id="sec-2-3"><h3>Efficacy after Long-Term Follow-up</h3><div role="paragraph">At the second data cutoff date, 1255 Covid-19 cases had been confirmed after the first dose. Among these confirmed cases, 738 had an onset of at least 7 days after the third dose and were evaluated as primary end-point cases. The mean (±SD) duration of follow-up, starting 7 days after the third dose, was 178.6±56.9 days in the ZF2001 group and 177.8±56.4 days in the placebo group. A total of 158 cases occurred among 12,625 participants in the ZF2001 group, and 580 cases occurred among 12,568 participants in the placebo group. These results yielded a vaccine efficacy of 75.7% (95% CI, 71.0 to 79.8) (<a href="#t2">Table 2</a>).</div><div role="paragraph">A time-to-event plot showed that the incidence of Covid-19 in the ZF2001 group and in the placebo group diverged immediately after the beginning of follow-up for the primary end-point analysis, a result indicating the start of protection (<a href="#f2">Figure 2B</a>). Among the participants who received at least one dose in the full analysis set for efficacy, a late onset of protection and low efficacy before the third dose were observed (<a href="#f2">Figure 2D</a> and Tables S10 and S11).</div><div role="paragraph">Vaccine efficacy against severe-to-critical Covid-19 was 87.6% (95% CI, 70.6 to 95.7), with confirmed cases of Covid-19 occurring in 6 participants in the ZF2001 group and in 43 participants in the placebo group. Vaccine efficacy against Covid-19–related death was 86.5% (95% CI, 38.9 to 98.5), with death occurring in 2 participants in the ZF2001 group and in 12 participants in the placebo group. Among the participants with coexisting medical conditions that were risk factors for severe Covid-19, vaccine efficacy was 61.6% (95% CI, 29.5 to 79.9). Among younger participants (18 to 59 years of age), vaccine efficacy was 76.0% (95% CI, 71.2 to 80.1), and among older participants (≥60 years of age), vaccine efficacy was 67.6% (95% CI, 21.9 to 87.8).</div><div role="paragraph">In a post hoc exploratory analysis of the 738 primary end-point cases, 626 swab samples yielded genotyping results, all of which showed SARS-CoV-2 variants. The three major variants were the delta (454 cases) and alpha (35 cases) variants of concern and the kappa variant of interest plus the B.1.617.3 variant (68 cases). Vaccine efficacy was 76.1% (95% CI, 70.0 to 81.2) against the delta variant, 88.3% (95% CI, 66.8 to 97.0) against the alpha variant, and 75.2% (95% CI, 55.3 to 87.0) against the kappa variant (<a href="#t2">Table 2</a>).</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">A total of 28,873 participants were included in the safety analysis set (14,448 in the ZF2001 group and 14,425 in the placebo group); 8 participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group in the safety analysis. At least one adverse event was reported by 11,957 (41.4%) participants — 6073 (42.0%) in the ZF2001 group and 5884 (40.8%) in the placebo group (<a href="#f3">Figure 3A</a>). Adverse events reported by 9588 participants (33.2%) were related to the investigational products, as determined by the trial investigators; the incidence of these events was similar in the trial groups (34.1% [4922 participants] in the ZF2001 group and 32.4% [4666 participants] in the placebo group). Within 7 days after each dose, 4730 participants (32.7%) in the ZF2001 group and 4481 participants (31.1%) in the placebo group reported having solicited reactions. Among the 4730 participants in the ZF2001 group, the incidence of local reactions was 18.8%, and the incidence of systemic reactions was 25.1%. The incidence of unsolicited reactions was low and similar in the two groups (5.5% in the ZF2001 group and 5.3% in the placebo group). In the ZF2001 group, the most common solicited local and systemic reactions were injection-site pain (in 17.3%) and headache (in 12.9%) (<a href="#f3">Figure 3B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f3.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/7120cef1-8a66-4a6d-bc0f-d9322de9b038/assets/images/large/nejmoa2202261_f3.jpg" height="2664" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Adverse Events at the Second Data Cutoff Date of December 15, 2021.</div><div class="notes"><div role="doc-footnote">Panel A shows the incidence of adverse events, both overall and according to age group, among the participants who received at least one dose of ZF2001 or placebo. Panel B shows the overall incidence of local and systemic adverse reactions. A total of 28,873 participants were included in the safety analysis set (14,448 in the ZF2001 group and 14,425 in the placebo group); 8 participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group for the safety analysis.</div></div></figcaption></figure></div><div role="paragraph">The overall reactogenicity was consistent with that reported in a phase 2 clinical trial of ZF2001.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-2" href-manipulated="true" aria-label="Reference 12">12</a></sup> In the current trial, 98.5% of the adverse reactions in the ZF2001 group were of grade 1 and 2, according to the criteria of the National Medical Products Administration (Tables S17 through S20), and 1.5% were of grade 3 or higher. The second and third injections did not further increase the incidence of adverse reactions (Table S21).</div><div role="paragraph">Serious adverse events were reported by 463 participants (1.6%) — 199 (1.4%) in the ZF2001 group and 264 (1.8%) in the placebo group (Table S23). A total of 4 participants (2 ZF2001 recipients and 2 placebo recipients) reported serious adverse events that were determined by the trial investigators to be related to the investigational products in terms of hypersensitivity. All symptoms resolved after medical treatment without sequelae (Table S24). A total of 48 deaths were documented, but none were attributed to the investigational products (Table S25). No cases of antibody-dependent enhancement or vaccine-enhanced disease were confirmed.</div><div role="paragraph">The incidence of adverse events was lower among the participants 60 years of age or older than among those 18 to 59 years of age (28.8% vs. 42.3%), as were the incidences of unsolicited and solicited adverse events and local and systemic reactions (<a href="#f3">Figure 3A</a>). Among the participants 60 years of age or older in the ZF2001 group, reactogenicity events were mainly grade 1 and 2 (96.7% of events), and no vaccine-related serious adverse events occurred.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">Whole inactivated virion, full-length spike, and RBD are the three major targets used in the currently approved Covid-19 vaccines.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup> RBD is a favorable vaccine target because it focuses the immune response on interference with receptor-binding activities.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-3" href-manipulated="true" aria-label="Reference 2">2</a></sup> Many RBD-based Covid-19 vaccines are under development, with some having been approved and some being evaluated in late stages of clinical trials.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r16 r29" id="body-ref-r29" href-manipulated="true">3,16,29</a></sup> Here, we report the clinical efficacy of an RBD-based Covid-19 vaccine and add a piece to the puzzle in understanding one of the major viral targets used in Covid-19 vaccines.</div><div role="paragraph">This trial was designed as a case-driven study. From the end of May to June 30, 2021, primary end-point cases accrued rapidly and quickly exceeded the case numbers required for both the interim and final analyses. Therefore, we decided to conduct the final analysis directly without interim evaluations and set the data cutoff date at June 30, 2021, although approximately 40% of the participants had not yet completed the assigned three-dose regimen. After June 30, 2021, these participants continued to complete the assigned trial regimen, and they were followed up for vaccine efficacy by the trial investigators over time. When the mean duration of follow-up for the primary end-point analysis reached 6 months, a second data cutoff date for an updated analysis, December 15, 2021, was set. At this date, most of the participants (87.3%) had been included in the primary efficacy analysis.</div><div role="paragraph">The three-dose ZF2001 regimen had a vaccine efficacy against Covid-19 of any severity of 81.4% in the short-term follow-up and 75.7% in the long-term follow-up. The waning of efficacy was small (Table S12). With an efficacy of more than 75% and a lower boundary of the 95% confidence interval of more than 30%, this vaccine met our prespecified criteria for success and exceeded the preferred criteria (≥70%) of WHO Target Product Profiles for Covid-19 vaccines.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> Vaccine efficacy against severe-to-critical disease was 92.9% in the short-term follow-up and 87.6% in the long-term follow-up. Therefore, ZF2001 would provide fundamental immunity to relieve the pressure on health care facilities that could be overwhelmed by patients with severe-to-critical Covid-19.</div><div role="paragraph">Clinical efficacy of Covid-19 vaccines against SARS-CoV-2 variants of concern is a global priority. Clinical efficacy against the alpha variant of concern has been reported for two vaccines; NVX-CoV2373 showed an efficacy of 93.6%<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-3" href-manipulated="true" aria-label="Reference 9">9</a></sup> and CVnCoV an efficacy of 55.1%.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6-2" href-manipulated="true" aria-label="Reference 6">6</a></sup> Real-world investigations have shown that the efficacy of vaccines against the delta variant of concern is lower than that against the alpha variant.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31 r32 r33" id="body-ref-r33" href-manipulated="true">31-33</a></sup> Clinical efficacy against the delta variant has been reported for two vaccines (BBV152 and SCB-2019).<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r15" id="body-ref-r15-3" href-manipulated="true">5,15</a></sup> Our phase 3 trial was conducted when new waves of infection became dominated by SARS-CoV-2 variants. The alpha variant was prevalent at the beginning of 2021 but was replaced by the delta variant in the next few months. The high cross-protection conferred by ZF2001 (an antigen based on the Wuhan-Hu-1 sequence) against different SARS-CoV-2 variants is encouraging. The vaccine showed an efficacy against the alpha variant of 92.7% in the short-term follow-up and 88.3% in the long-term follow-up; an efficacy against the delta variant of 81.4% and 76.1%, respectively; and an efficacy against the kappa variant of interest of 84.8% and 75.2%, respectively. The reduced efficacy against the delta variant and the kappa variant plus the B.1.617.3 variant from that against the alpha variant was consistent with the trends shown in our previous research involving the use of a pseudovirus neutralization assay.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24" id="body-ref-r24-2" href-manipulated="true">23,24</a></sup></div><div role="paragraph">This trial involving a large cohort of participants confirmed the acceptable safety and reactogenicity profile of ZF2001 that was shown in our previous phase 1 and 2 trials in smaller cohorts.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-2" href-manipulated="true" aria-label="Reference 21">21</a></sup> The overall incidence of adverse events was similar to that in our phase 2 trial but was more balanced between the ZF2001 group and the placebo group, presumably owing to the larger population in the phase 3 trial. Adverse events of grade 3 or higher in the ZF2001 group were uncommon in both trials, with an incidence of 2.7% in the phase 2 trial and 1.5% in the phase 3 trial, and serious adverse events that were determined to be related to ZF2001 were rare, with no events in the phase 2 trial and 2 events in the phase 3 trial. In addition, older participants (≥60 years of age) were included in this phase 3 trial, and the incidence of adverse and reactogenicity events among them was lower than that among the younger participants (18 to 59 years of age). These findings support the good safety profiles of protein subunit vaccines that use an aluminum adjuvant, as has been reported for the licensed vaccines against hepatitis B and human papillomavirus infections.<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34 r35" id="body-ref-r35" href-manipulated="true">34,35</a></sup></div><div role="paragraph">This trial has several limitations. First, most of the participants were Asian (78.5%). We welcome further investigation in a more diverse cohort. Second, recruitment of participants 60 years of age or older was lower than anticipated, and the vaccine efficacies of 87.6% in the short-term follow-up and 67.6% in the long-term follow-up of the older participants were insufficient, given the lower boundaries of the 95% confidence intervals of less than 30% (2.5% and 21.9%, respectively). Vaccine effectiveness in older populations should be further evaluated in real-world settings. Third, this trial was not designed to address the vaccine efficacy against asymptomatic infections. Given the possible importance of asymptomatic infections with respect to virus transmission, we welcome a new trial to test the efficacy of ZF2001 against these infections. Fourth, an imbalance of severe-to-critical Covid-19 cases was observed in favor of the placebo group in the early dosing period (Fig. S3), particularly between dose 1 and 2, as indicated by negative vaccine efficacy (Table S11). This imbalance could represent a risk of vaccine-enhanced disease or may simply be a chance finding related to the limited sample size. The results of post hoc landmark analyses did not support a significant incidence of vaccine-enhanced disease in the early dosing period (Fig. S4). However, postmarket surveillance for imbalances in cases of severe Covid-19 needs to be conducted thoroughly.</div><div role="paragraph">Overall, this trial provides clinical evidence that an RBD-based vaccine is a promising alternative in the prevention of symptomatic Covid-19.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on May 4, 2022, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant from the <span class="named-content" data-type="funder">National Science and Technology Major Project</span> (2020YFA0907100), a grant from the <span class="named-content" data-type="funder">National Natural Science Foundation of China</span> (81991494), and an intramural special grant for SARS-CoV-2 research from the <span class="named-content" data-type="funder">Chinese Academy of Sciences</span> and by <span class="named-content" data-type="funder">Anhui Zhifei Longcom Biopharmaceutical</span>. Dr. Dai is supported by grants from the <span class="named-content" data-type="funder">National Natural Science Foundation of China</span> (82122031) and the <span class="named-content" data-type="funder">Chinese Academy of Sciences</span> (YSBR-010).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the members of the end-point adjudication committee and the data safety and monitoring board for their diligent review of the data; the participants who volunteered to be part of this study; the members of the clinical research teams at the participating sites; the members involved in contract clinical research organization (Chongqing Medleader Bio-Pharm, China; the Center for Advanced Technologies, Uzbekistan; DRK Pharma Solutions, Pakistan; and Accuracy Research, Ecuador); and Yuxuan Zheng (Institute of Microbiology, Chinese Academy of Sciences) and Jingxin Li and Fengcai Zhu (Jiangsu Provincial Center for Disease Control and Prevention) for their technical support in the data analyses.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2202261_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202261/suppl_file/nejmoa2202261_protocol.pdf" download="nejmoa2202261_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202261_protocol.pdf" data-doi="10.1056/NEJMoa2202261">Download</a></li><li>1.77 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2202261_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202261/suppl_file/nejmoa2202261_appendix.pdf" download="nejmoa2202261_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202261_appendix.pdf" data-doi="10.1056/NEJMoa2202261">Download</a></li><li>1.14 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2202261_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202261/suppl_file/nejmoa2202261_disclosures.pdf" download="nejmoa2202261_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202261_disclosures.pdf" data-doi="10.1056/NEJMoa2202261">Download</a></li><li>650.36 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2202261_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202261/suppl_file/nejmoa2202261_data-sharing.pdf" download="nejmoa2202261_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202261_data-sharing.pdf" data-doi="10.1056/NEJMoa2202261">Download</a></li><li>71.63 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Gao GF. Science-based COVID-19 vaccine development. <em>Natl Sci Rev</em> 2021;8:nwab193-nwab193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nsr/nwab193" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34858619/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000720750500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Science-based+COVID-19+vaccine+development.&amp;publication_year=2021&amp;journal=Natl+Sci+Rev&amp;pages=nwab193-nwab193&amp;doi=10.1093%2Fnsr%2Fnwab193&amp;pmid=34858619" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Dai L, Gao GF. Viral targets for vaccines against COVID-19. <em>Nat Rev Immunol</em> 2021;21:73-82.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41577-020-00480-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33340022/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000600085200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Viral+targets+for+vaccines+against+COVID-19.&amp;publication_year=2021&amp;journal=Nat+Rev+Immunol&amp;pages=73-82&amp;doi=10.1038%2Fs41577-020-00480-0&amp;pmid=33340022" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the cornerstone of pandemic control. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the currently approved Covid-19 vaccines. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] with receptor-binding activities. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">COVID-19 vaccine tracker. Approved vaccines (<a href="https://covid19.trackvaccines.org/vaccines/approved">https://covid19.trackvaccines.org/vaccines/approved</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=COVID-19+vaccine+tracker.+Approved+vaccines+%28https%3A%2F%2Fcovid19.trackvaccines.org%2Fvaccines%2Fapproved%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the cornerstone of pandemic control. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] are in late stages of clinical trials </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] China, Uzbekistan, Indonesia, and Colombia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in late stages of clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. <em>JAMA</em> 2021;326:35-45.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2021.8565" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34037666/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000655672100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+2+inactivated+SARS-CoV-2+vaccines+on+symptomatic+COVID-19+infection+in+adults%3A+a+randomized+clinical+trial.&amp;publication_year=2021&amp;journal=JAMA&amp;pages=35-45&amp;doi=10.1001%2Fjama.2021.8565&amp;pmid=34037666" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. <em>Lancet</em> 2021;398:2173-2184.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)02000-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34774196/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000729467800005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+lot-to-lot+immunogenicity+of+an+inactivated+SARS-CoV-2+vaccine+%28BBV152%29%3A+interim+results+of+a+randomised%2C+double-blind%2C+controlled%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=2173-2184&amp;doi=10.1016%2FS0140-6736%2821%2902000-6&amp;pmid=34774196" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] was shown to have an efficacy of 65.2%, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for two vaccines (BBV152 and SCB-2019). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <em>Lancet Infect Dis</em> 2022;22:329-340.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(21)00677-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34826381/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000762437600028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+the+CVnCoV+SARS-CoV-2+mRNA+vaccine+candidate+in+ten+countries+in+Europe+and+Latin+America+%28HERALD%29%3A+a+randomised%2C+observer-blinded%2C+placebo-controlled%2C+phase+2b%2F3+trial.&amp;publication_year=2022&amp;journal=Lancet+Infect+Dis&amp;pages=329-340&amp;doi=10.1016%2FS1473-3099%2821%2900677-0&amp;pmid=34826381" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and CVnCoV an efficacy of 55.1%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. <em>Lancet</em> 2021;397:671-681.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00234-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33545094/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000620991800029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+an+rAd26+and+rAd5+vector-based+heterologous+prime-boost+COVID-19+vaccine%3A+an+interim+analysis+of+a+randomised+controlled+phase+3+trial+in+Russia.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=671-681&amp;doi=10.1016%2FS0140-6736%2821%2900234-8&amp;pmid=33545094" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. <em>N Engl J Med</em> 2021;384:403-416.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2035389&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33378609/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000629333200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+the+mRNA-1273+SARS-CoV-2+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=403-416&amp;doi=10.1056%2FNEJMoa2035389&amp;pmid=33378609" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] shown to have an efficacy of 90 to 96%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. <em>N Engl J Med</em> 2022;386:531-543.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2116185&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34910859/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000730408900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+NVX-CoV2373+in+adults+in+the+United+States+and+Mexico.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=531-543&amp;doi=10.1056%2FNEJMoa2116185&amp;pmid=34910859" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] shown to have an efficacy of 90 to 96%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] NVX-CoV2373 showed an efficacy of 93.6% </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. <em>N Engl J Med</em> 2021;385:2348-2360.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2105290&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34587382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000701157100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+3+safety+and+efficacy+of+AZD1222+%28ChAdOx1+nCoV-19%29+Covid-19+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2348-2360&amp;doi=10.1056%2FNEJMoa2105290&amp;pmid=34587382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. <em>N Engl J Med</em> 2021;385:1172-1183.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2107659&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34192426/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000669588900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+NVX-CoV2373+Covid-19+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1172-1183&amp;doi=10.1056%2FNEJMoa2107659&amp;pmid=34192426" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. <em>N Engl J Med</em> 2021;384:2187-2201.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_13_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2101544&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33882225/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000642260000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+single-dose+Ad26.COV2.S+vaccine+against+Covid-19.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2187-2201&amp;doi=10.1056%2FNEJMoa2101544&amp;pmid=33882225" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in a phase 2 clinical trial of ZF2001. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. <em>N Engl J Med</em> 2020;383:2603-2615.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_14_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2034577&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33301246/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605648000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2603-2615&amp;doi=10.1056%2FNEJMoa2034577&amp;pmid=33301246" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] shown to have an efficacy of 90 to 96%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. <em>Lancet</em> 2022;399:237-248.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)02753-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34953526/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000746041700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Final+efficacy+analysis%2C+interim+safety+analysis%2C+and+immunogenicity+of+a+single+dose+of+recombinant+novel+coronavirus+vaccine+%28adenovirus+type+5+vector%29+in+adults+18+years+and+older%3A+an+international%2C+multicentre%2C+randomised%2C+double-blinded%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2022&amp;journal=Lancet&amp;pages=237-248&amp;doi=10.1016%2FS0140-6736%2821%2902753-7&amp;pmid=34953526" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. <em>Lancet</em> 2022;399:461-472.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(22)00055-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35065705/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000755141600026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+adjuvanted+subunit+protein+COVID-19+vaccine%2C+SCB-2019%3A+a+phase+2+and+3+multicentre%2C+double-blind%2C+randomised%2C+placebo-controlled+trial.&amp;publication_year=2022&amp;journal=Lancet&amp;pages=461-472&amp;doi=10.1016%2FS0140-6736%2822%2900055-1&amp;pmid=35065705" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] was shown to have an efficacy of 78.7%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for two vaccines (BBV152 and SCB-2019). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">COVID-19 vaccine tracker and landscape. Geneva: World Health Organization, March 29, 2022 (<a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=COVID-19+vaccine+tracker+and+landscape.+Geneva%3A+World+Health+Organization%2C+March+29%2C+2022+%28https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fdraft-landscape-of-covid-19-candidate-vaccines%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] are in late stages of clinical trials </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in late stages of clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. <em>Nature</em> 2021;600:408-418.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-021-04188-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34880490/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000728552800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+emergence%2C+genomic+diversity+and+global+spread+of+SARS-CoV-2.&amp;publication_year=2021&amp;journal=Nature&amp;pages=408-418&amp;doi=10.1038%2Fs41586-021-04188-6&amp;pmid=34880490" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Pormohammad A, Zarei M, Ghorbani S, et al. Effectiveness of COVID-19 vaccines against delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies. <em>Vaccines (Basel)</em> 2021;10:23-23.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3390/vaccines10010023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35062684/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000761990100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+COVID-19+vaccines+against+delta+%28B.1.617.2%29+variant%3A+a+systematic+review+and+meta-analysis+of+clinical+studies.&amp;publication_year=2021&amp;journal=Vaccines+%28Basel%29&amp;pages=23-23&amp;doi=10.3390%2Fvaccines10010023&amp;pmid=35062684" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. <em>Cell</em> 2020;182(3):722-733.e11.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.06.035" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32645327/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000558649000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+universal+design+of+betacoronavirus+vaccines+against+COVID-19%2C+MERS%2C+and+SARS.&amp;publication_year=2020&amp;journal=Cell&amp;pages=722-733.e11&amp;doi=10.1016%2Fj.cell.2020.06.035&amp;pmid=32645327" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">An Y, Li S, Jin X, et al. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. <em>Emerg Microbes Infect</em> 2022;11:1058-1071.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35311493/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+tandem-repeat+dimeric+RBD+protein-based+covid-19+vaccine+zf2001+protects+mice+and+nonhuman+primates.&amp;publication_year=2022&amp;pages=1058-1071&amp;pmid=35311493" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <em>Lancet Infect Dis</em> 2021;21:1107-1119.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(21)00127-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33773111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000680046200042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+recombinant+tandem-repeat+dimeric+RBD-based+protein+subunit+vaccine+%28ZF2001%29+against+COVID-19+in+adults%3A+two+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+1+and+2+trials.&amp;publication_year=2021&amp;journal=Lancet+Infect+Dis&amp;pages=1107-1119&amp;doi=10.1016%2FS1473-3099%2821%2900127-4&amp;pmid=33773111" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] was selected for use in a phase 3 trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] phase 1 and 2 trials in smaller cohorts. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Huang B, Dai L, Wang H, et al. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. <em>Lancet Microbe</em> 2021;2(7):e285-e285.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2666-5247(21)00082-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33870240/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Serum+sample+neutralisation+of+BBIBP-CorV+and+ZF2001+vaccines+to+SARS-CoV-2+501Y.V2.&amp;publication_year=2021&amp;journal=Lancet+Microbe&amp;pages=e285-e285&amp;doi=10.1016%2FS2666-5247%2821%2900082-3&amp;pmid=33870240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Zhao X, Zheng A, Li D, et al. Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. <em>Lancet Microbe</em> 2021;2(10):e494-e494.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2666-5247(21)00217-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34458880/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neutralisation+of+ZF2001-elicited+antisera+to+SARS-CoV-2+variants.&amp;publication_year=2021&amp;journal=Lancet+Microbe&amp;pages=e494-e494&amp;doi=10.1016%2FS2666-5247%2821%2900217-2&amp;pmid=34458880" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] delta, B.1.617.1 (kappa), and omicron, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] use of a pseudovirus neutralization assay. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Zhao X, Li D, Ruan W, et al. Effects of a prolonged booster interval on neutralization of omicron variant. <em>N Engl J Med</em> 2022;386:894-896.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_25_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMc2119426&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35081296/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000747075500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+a+prolonged+booster+interval+on+neutralization+of+omicron+variant.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=894-896&amp;doi=10.1056%2FNEJMc2119426&amp;pmid=35081296" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] delta, B.1.617.1 (kappa), and omicron, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] use of a pseudovirus neutralization assay. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">An international randomised trial of candidate vaccines against COVID-19. Geneva: World Health Organization, May 28, 2020 (<a href="https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19">https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=An+international+randomised+trial+of+candidate+vaccines+against+COVID-19.+Geneva%3A+World+Health+Organization%2C+May+28%2C+2020+%28https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fan-international-randomised-trial-of-candidate-vaccines-against-covid-19%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Design of vaccine efficacy trials to be used during public health emergencies — points of considerations and key principles. Geneva: World Health Organization, 2019 (<a href="https://www.who.int/docs/default-source/blue-print/working-group-for-vaccine-evaluation-(4th-consultation)/ap1-guidelines-online-consultation.pdf">https://www.who.int/docs/default-source/blue-print/working-group-for-vaccine-evaluation-(4th-consultation)/ap1-guidelines-online-consultation.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Design+of+vaccine+efficacy+trials+to+be+used+during+public+health+emergencies+%E2%80%94+points+of+considerations+and+key+principles.+Geneva%3A+World+Health+Organization%2C+2019+%28https%3A%2F%2Fwww.who.int%2Fdocs%2Fdefault-source%2Fblue-print%2Fworking-group-for-vaccine-evaluation-%284th-consultation%29%2Fap1-guidelines-online-consultation.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. <em>Commun Stat Theory Methods</em> 1998;27:1305-1322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03610929808832160" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000073860500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Exact+power+and+sample+size+for+vaccine+efficacy+studies.&amp;publication_year=1998&amp;journal=Commun+Stat+Theory+Methods&amp;pages=1305-1322&amp;doi=10.1080%2F03610929808832160" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. <em>Biometrics</em> 1979;35:549-556.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2307/2530245" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/497341/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1979HM72500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multiple+testing+procedure+for+clinical+trials.&amp;publication_year=1979&amp;journal=Biometrics&amp;pages=549-556&amp;doi=10.2307%2F2530245&amp;pmid=497341" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Kleanthous H, Silverman JM, Makar KW, Yoon IK, Jackson N, Vaughn DW. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <em>NPJ Vaccines</em> 2021;6:128-128.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41541-021-00393-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34711846/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000712410100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Scientific+rationale+for+developing+potent+RBD-based+vaccines+targeting+COVID-19.&amp;publication_year=2021&amp;journal=NPJ+Vaccines&amp;pages=128-128&amp;doi=10.1038%2Fs41541-021-00393-6&amp;pmid=34711846" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">WHO target product profiles for COVID-19 vaccines. Geneva: World Health Organization, April 9, 2020 (<a href="https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines">https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=WHO+target+product+profiles+for+COVID-19+vaccines.+Geneva%3A+World+Health+Organization%2C+April+9%2C+2020+%28https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fwho-target-product-profiles-for-covid-19-vaccines%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. <em>N Engl J Med</em> 2021;385:585-594.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_32_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2108891&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34289274/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000675554200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+Covid-19+vaccines+against+the+B.1.617.2+%28delta%29+variant.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=585-594&amp;doi=10.1056%2FNEJMoa2108891&amp;pmid=34289274" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <em>BMJ</em> 2021;375:e068848-e068848.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34911691/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000732451800013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+mRNA-1273+against+delta%2C+mu%2C+and+other+emerging+variants+of+SARS-CoV-2%3A+test+negative+case-control+study.&amp;publication_year=2021&amp;journal=BMJ&amp;pages=e068848-e068848&amp;pmid=34911691" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar. <em>Nat Med</em> 2021;27:2136-2143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-021-01583-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34728831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000713960400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+and+mRNA-1273+COVID-19+vaccine+effectiveness+against+the+SARS-CoV-2+delta+variant+in+Qatar.&amp;publication_year=2021&amp;journal=Nat+Med&amp;pages=2136-2143&amp;doi=10.1038%2Fs41591-021-01583-4&amp;pmid=34728831" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. <em>Plotkin’s vaccines. 7th ed</em>. Philadelphia: Elsevier, 2018:342-374.e17.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/B978-0-323-35761-6.00025-0" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hepatitis+B+vaccines&amp;publication_year=2018&amp;pages=342-374.e17&amp;doi=10.1016%2FB978-0-323-35761-6.00025-0" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. <em>Plotkin’s vaccines. 7th ed</em>. Philadelphia: Elsevier, 2018:430-455.e10.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/B978-0-323-35761-6.00030-4" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+vaccines&amp;publication_year=2018&amp;pages=430-455.e10&amp;doi=10.1016%2FB978-0-323-35761-6.00030-4" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/22"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">22</span></span> • <span property="datePublished">June 2, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2097</span>-<span property="pageEnd">2111</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2202261" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2202261?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: May 4, 2022</div><div><b class="core-label">Published in issue</b>: June 2, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/coronavirus" alt="View article keyword Coronavirus" data-interactiontype="article_recirculation_click">Coronavirus</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/vaccines" alt="View article keyword Vaccines" data-interactiontype="article_recirculation_click">Vaccines</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Lianpan</span> <span property="familyName">Dai</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lidong</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">M.S.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3869-615X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-3869-615X</a></span>, <span property="author" typeof="Person"><span property="givenName">Lifeng</span> <span property="familyName">Tao</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sri R.</span> <span property="familyName">Hadinegoro</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Musabaev</span> <span property="familyName">Erkin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zhifang</span> <span property="familyName">Ying</span>, <span property="honorificSuffix">B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peng</span> <span property="familyName">He</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rodman T.</span> <span property="familyName">Girsang</span>, <span property="honorificSuffix">M.Hlth.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hugo</span> <span property="familyName">Vergara</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Javed</span> <span property="familyName">Akram</span>, <span property="honorificSuffix">F.R.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hindra I.</span> <span property="familyName">Satari</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tanwir</span> <span property="familyName">Khaliq</span>, <span property="honorificSuffix">F.C.P.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ume</span> <span property="familyName">Sughra</span>, <span property="honorificSuffix">F.R.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ana P.</span> <span property="familyName">Celi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fangjun</span> <span property="familyName">Li</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yan</span> <span property="familyName">Li</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zhiwei</span> <span property="familyName">Jiang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dilbar</span> <span property="familyName">Dalimova</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jaloliddin</span> <span property="familyName">Tuychiev</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shahlo</span> <span property="familyName">Turdikulova</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Aamer</span> <span property="familyName">Ikram</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nancy</span> <span property="familyName">Flores Lastra</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fan</span> <span property="familyName">Ding</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mahendra</span> <span property="familyName">Suhardono</span>, <span property="honorificSuffix">M.M.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eddy</span> <span property="familyName">Fadlyana</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jinghua</span> <span property="familyName">Yan</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zhongyu</span> <span property="familyName">Hu</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Changgui</span> <span property="familyName">Li</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ibrokhim Y.</span> <span property="familyName">Abdurakhmonov</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">George F.</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">D.Phil.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3869-615X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-3869-615X</a></span>, for <span property="author" typeof="Person">the ZF2001 Global Trial Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (L.D., Y.L., J.Y., G.F.G.), the National Institute for Food and Drug Control (Z.Y., P.H., Z.H., C.L.), and Beijing Keytech Statistical Technology (Z.J.), Beijing, the Hunan Provincial Center for Disease Control and Prevention, Changsha (L.G., F.L.), and Anhui Zhifei Longcom Biopharmaceutical, Hefei (L.T., F.D.) — all in China; the Child Health Department, Faculty of Medicine, University of Indonesia, and Cipto Mangunkusumo Hospital (S.R.H., H.I.S.), and PT Jakarta Biopharmaceutical Industry (M.S.), Jakarta, and the Child Health Department, Faculty of Medicine, Padjadjaran University, and Hasan Sadikin General Hospital, Bandung (R.T.G., E.F.) — all in Indonesia; the Research Institute of Virology (M.E., J.T.), the Center for Advanced Technologies (D.D., S.T.), and the Center of Genomics and Bioinformatics (I.Y.A.) — all in Tashkent, Uzbekistan; Biodimed Unidad Alemania (H.V.), the Department of Infectiology, Novaclínica Santa Cecilia (A.P.C.), and Biodimed Unidad Eloy Alfaro (N.F.L.) — all in Quito, Ecuador; and University of Health Sciences Lahore, Lahore (J.A.), Shaheed Zulfiqar Ali Bhutto Medical University (T.K.) and the National Institute of Health (A.I.), Islamabad, and Al-Shifa Trust Eye Hospital, Rawalpindi (U.S.) — all in Pakistan.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. G.F. Gao can be contacted at <a href="mailto:gaof@im.ac.cn">gaof@im.ac.cn</a> or at CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, No. 1 Beichen West Rd., Chaoyang District, Beijing 100101, China.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the members of the ZF2001 Global Trial Group is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Dr. Dai, Mr. L. Gao, Drs. Hadinegoro and Erkin, Ms. Ying, Ms. Hu, and Drs. C. Li and Abdurakhmonov contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">204</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2202261" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="f300f47e-e37a-70b4-04d5-7b43f751fca8"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921" style="display:inline-block;">
                <img alt="Article has an altmetric score of 152" src="https://badges.altmetric.com/?size=320&amp;score=152&amp;types=mabrtttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_f300f47e-e37a-70b4-04d5-7b43f751fca8" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921&amp;tab=news">
          Picked up by <b>11</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921&amp;tab=twitter">
          Posted by <b>99</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=127706921&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>233</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6d4f893d13289-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2202261"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-22%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2202261" data-lazyload="false" data-total="204" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wasim Aluísio Prates-Syed, </li><li class="list-inline-item cited-by__entry__author">Dennyson Leandro Mathias da Fonseca, </li><li class="list-inline-item cited-by__entry__author">Shahab Zaki Pour, </li><li class="list-inline-item cited-by__entry__author">Aline Lira, </li><li class="list-inline-item cited-by__entry__author">Nelson Cortes, </li><li class="list-inline-item cited-by__entry__author">Jaqueline Dinis Queiroz Silva, </li><li class="list-inline-item cited-by__entry__author">Evelyn Carvalho, </li><li class="list-inline-item cited-by__entry__author">Igor Salerno Filgueiras, </li><li class="list-inline-item cited-by__entry__author">Tania Geraldine Churascari Vinces, </li><li class="list-inline-item cited-by__entry__author">Lena F. Schimke, </li><li class="list-inline-item cited-by__entry__author">Lorena C. S. Chaves, </li><li class="list-inline-item cited-by__entry__author">Gerhard Wunderlich, </li><li class="list-inline-item cited-by__entry__author">Ricardo Durães-Carvalho, </li><li class="list-inline-item cited-by__entry__author">Haroldo Dutra Dias, </li><li class="list-inline-item cited-by__entry__author">Hans D. Ochs, </li><li class="list-inline-item cited-by__entry__author">Niels O. S. Câmara, </li><li class="list-inline-item cited-by__entry__author">Helder I. Nakaya, </li><li class="list-inline-item cited-by__entry__author">José E. Krieger, </li><li class="list-inline-item cited-by__entry__author">Otavio Cabral-Marques, </li><li class="list-inline-item cited-by__entry__author">Gustavo Cabral-Miranda, </li></ul><span class="cited-by__entry__title">COVID-19 vaccination atlas using an integrative systems vaccinology approach, </span><span class="cited-by__entry__series-title">npj Vaccines, </span><span class="cited-by__entry__volume"><strong>10</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41541-025-01148-3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41541-025-01148-3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41541-025-01148-3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Peng Zhu, </li><li class="list-inline-item cited-by__entry__author">Yan Chen, </li><li class="list-inline-item cited-by__entry__author">Xia Xu, </li><li class="list-inline-item cited-by__entry__author">Deyong Tan, </li><li class="list-inline-item cited-by__entry__author">Ledong Xiao, </li><li class="list-inline-item cited-by__entry__author">Chengling Liao, </li><li class="list-inline-item cited-by__entry__author">Huan Xia, </li><li class="list-inline-item cited-by__entry__author">Ting Zhang, </li><li class="list-inline-item cited-by__entry__author">Jing Zou, </li><li class="list-inline-item cited-by__entry__author">Xuan Chen, </li><li class="list-inline-item cited-by__entry__author">Man Li, </li><li class="list-inline-item cited-by__entry__author">Yang Yang, </li><li class="list-inline-item cited-by__entry__author">Jian Zhou, </li><li class="list-inline-item cited-by__entry__author">Jia Liu, </li><li class="list-inline-item cited-by__entry__author">Wei Zhang, </li><li class="list-inline-item cited-by__entry__author">Honghao Zhou, </li><li class="list-inline-item cited-by__entry__author">Qing Li, </li></ul><span class="cited-by__entry__title">Antibody response after SARS-CoV-2 infection or vaccination in China: A cross-sectional study, </span><span class="cited-by__entry__series-title">Vaccine: X, </span><span class="cited-by__entry__volume"><strong>24</strong>, </span><span class="cited-by__entry__page-range">(100644), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jvacx.2025.100644" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jvacx.2025.100644</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jvacx.2025.100644" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Laura A. Bruno, </li><li class="list-inline-item cited-by__entry__author">Celeste Pueblas Castro, </li><li class="list-inline-item cited-by__entry__author">Agostina Demaría, </li><li class="list-inline-item cited-by__entry__author">Lineia Prado, </li><li class="list-inline-item cited-by__entry__author">Clara G. Fascetto Cassero, </li><li class="list-inline-item cited-by__entry__author">Lucas M. Saposnik, </li><li class="list-inline-item cited-by__entry__author">Federico Páez Córdoba, </li><li class="list-inline-item cited-by__entry__author">Juan Manuel Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Giulia Piccini, </li><li class="list-inline-item cited-by__entry__author">Roberta Antonelli, </li><li class="list-inline-item cited-by__entry__author">Giulia Lapini, </li><li class="list-inline-item cited-by__entry__author">Nigel Temperton, </li><li class="list-inline-item cited-by__entry__author">Sabrina A. Del Priore, </li><li class="list-inline-item cited-by__entry__author">Andres C. Hernando Insua, </li><li class="list-inline-item cited-by__entry__author">Ingrid G. Kaufmann, </li><li class="list-inline-item cited-by__entry__author">Julio C. Vega, </li><li class="list-inline-item cited-by__entry__author">Juan M. Flo, </li><li class="list-inline-item cited-by__entry__author">Karina A. Pasquevich, </li><li class="list-inline-item cited-by__entry__author">Lorena M. Coria, </li><li class="list-inline-item cited-by__entry__author">Juliana Cassataro, </li></ul><span class="cited-by__entry__title">Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity, </span><span class="cited-by__entry__series-title">npj Vaccines, </span><span class="cited-by__entry__volume"><strong>10</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41541-025-01156-3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41541-025-01156-3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41541-025-01156-3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xiao-Qiang Liu, </li><li class="list-inline-item cited-by__entry__author">Yang-Yang Qi, </li><li class="list-inline-item cited-by__entry__author">Tao Huang, </li><li class="list-inline-item cited-by__entry__author">Li-Li Huang, </li><li class="list-inline-item cited-by__entry__author">Ming-Xuan Zhao, </li><li class="list-inline-item cited-by__entry__author">Zhong-Fang Wang, </li><li class="list-inline-item cited-by__entry__author">Jun Dai, </li><li class="list-inline-item cited-by__entry__author">Yan-Xia Wang, </li><li class="list-inline-item cited-by__entry__author">Jing-Jing Chen, </li><li class="list-inline-item cited-by__entry__author">Xiao-Yun Yang, </li><li class="list-inline-item cited-by__entry__author">Hui-Lan Fan, </li><li class="list-inline-item cited-by__entry__author">Xue-Mei Yan, </li><li class="list-inline-item cited-by__entry__author">Jian-Chang He, </li><li class="list-inline-item cited-by__entry__author">Yan-Xiang Zou, </li><li class="list-inline-item cited-by__entry__author">Zhi-Wei Jiang, </li><li class="list-inline-item cited-by__entry__author">Zhi-Fei Zhan, </li><li class="list-inline-item cited-by__entry__author">Si-Wen Tao, </li><li class="list-inline-item cited-by__entry__author">De-Fang Dai, </li><li class="list-inline-item cited-by__entry__author">Feng Shi, </li><li class="list-inline-item cited-by__entry__author">Qiong-Na Zhang, </li><li class="list-inline-item cited-by__entry__author">Xiu-Liang Yang, </li><li class="list-inline-item cited-by__entry__author">Xiao-Zhong Li, </li><li class="list-inline-item cited-by__entry__author">Wei Li, </li><li class="list-inline-item cited-by__entry__author">Jing Lu, </li><li class="list-inline-item cited-by__entry__author">Jiang-Bing Zheng, </li><li class="list-inline-item cited-by__entry__author">Zhi-Hua Zhang, </li><li class="list-inline-item cited-by__entry__author">Gao-Xiang Chen, </li><li class="list-inline-item cited-by__entry__author">Hong Su, </li><li class="list-inline-item cited-by__entry__author">Wei-Min Gao, </li><li class="list-inline-item cited-by__entry__author">Lorenz von Seidlein, </li><li class="list-inline-item cited-by__entry__author">Xuan-Yi Wang, </li><li class="list-inline-item cited-by__entry__author">Lin Yuan, </li><li class="list-inline-item cited-by__entry__author">Jin-Zhong Lin, </li></ul><span class="cited-by__entry__title">Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial, </span><span class="cited-by__entry__series-title">Human Vaccines &amp; Immunotherapeutics, </span><span class="cited-by__entry__volume"><strong>21</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/21645515.2025.2502250" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/21645515.2025.2502250</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/21645515.2025.2502250" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Aviraj K. S, </li><li class="list-inline-item cited-by__entry__author">Apoorva Wasnik, </li><li class="list-inline-item cited-by__entry__author">Lalima Gupta, </li><li class="list-inline-item cited-by__entry__author">Ayushi Ranjan, </li><li class="list-inline-item cited-by__entry__author">Harshini Suresh, </li></ul><span class="cited-by__entry__title">Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">Systematic Reviews, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13643-025-02856-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13643-025-02856-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13643-025-02856-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rong Zhang, </li><li class="list-inline-item cited-by__entry__author">Dedong Li, </li><li class="list-inline-item cited-by__entry__author">Pengyue Gao, </li><li class="list-inline-item cited-by__entry__author">Wenjing Ruan, </li><li class="list-inline-item cited-by__entry__author">Shitong Qiao, </li><li class="list-inline-item cited-by__entry__author">Senyu Xu, </li><li class="list-inline-item cited-by__entry__author">Lianpan Dai, </li><li class="list-inline-item cited-by__entry__author">Tingrong Luo, </li><li class="list-inline-item cited-by__entry__author">Xin Zhao, </li><li class="list-inline-item cited-by__entry__author">George F. Gao, </li></ul><span class="cited-by__entry__title">A SARS‐CoV and SARS‐CoV‐2 RBD Heterodimer Vaccine Candidate, </span><span class="cited-by__entry__series-title">Journal of Medical Virology, </span><span class="cited-by__entry__volume"><strong>97</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/jmv.70367" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/jmv.70367</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/jmv.70367" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xin Zhang, </li><li class="list-inline-item cited-by__entry__author">Li Li, </li><li class="list-inline-item cited-by__entry__author">Yongmei Liu, </li><li class="list-inline-item cited-by__entry__author">Haoting Zhan, </li><li class="list-inline-item cited-by__entry__author">Muwei Dai, </li><li class="list-inline-item cited-by__entry__author">Kun Zhang, </li><li class="list-inline-item cited-by__entry__author">Huimin Yan, </li><li class="list-inline-item cited-by__entry__author">Huixia Gao, </li><li class="list-inline-item cited-by__entry__author">Jingwen Liu, </li><li class="list-inline-item cited-by__entry__author">Shifu Liu, </li><li class="list-inline-item cited-by__entry__author">Weina Lu, </li><li class="list-inline-item cited-by__entry__author">Yongzhe Li, </li><li class="list-inline-item cited-by__entry__author">Aidong Feng, </li><li class="list-inline-item cited-by__entry__author">Erhei Dai, </li><li class="list-inline-item cited-by__entry__author">Junying Zhou, </li></ul><span class="cited-by__entry__title">Mass Cytometry Analysis of High-Dimensional Single-Cell Immune Profiles in ZF2001-Vaccinated Patients Infected with SARS-CoV-2, </span><span class="cited-by__entry__series-title">Infection and Drug Resistance, </span><span class="cited-by__entry__volume"><strong>Volume 18</strong>, </span><span class="cited-by__entry__page-range">(2497-2509), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.2147/IDR.S511936" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.2147/IDR.S511936</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.2147/IDR.S511936" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Chendong Yang, </li><li class="list-inline-item cited-by__entry__author">Entao Li, </li><li class="list-inline-item cited-by__entry__author">Xiaoping Guo, </li><li class="list-inline-item cited-by__entry__author">Wenyu Xie, </li><li class="list-inline-item cited-by__entry__author">Yuanzhan Wang, </li><li class="list-inline-item cited-by__entry__author">Xuefei Huang, </li><li class="list-inline-item cited-by__entry__author">Sandra Chiu, </li><li class="list-inline-item cited-by__entry__author">Xuanjun Wu, </li></ul><span class="cited-by__entry__title">A Self-Assembled Nanovaccine with BA.4/5 Receptor-Binding Domain and CpG Oligodeoxynucleotides Induces Broad-Spectrum Neutralization against SARS-CoV-2 Omicron Subvariants, </span><span class="cited-by__entry__series-title">ACS Nano, </span><span class="cited-by__entry__volume"><strong>19</strong>, </span><span class="cited-by__entry__issue">17, </span><span class="cited-by__entry__page-range">(16424-16437), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1021/acsnano.4c17269" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1021/acsnano.4c17269</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1021/acsnano.4c17269" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ruimin Sun, </li><li class="list-inline-item cited-by__entry__author">Lijuan Xia, </li><li class="list-inline-item cited-by__entry__author">Guangbiao She, </li><li class="list-inline-item cited-by__entry__author">Jinrong Li, </li><li class="list-inline-item cited-by__entry__author">Yiru Wang, </li><li class="list-inline-item cited-by__entry__author">Yunxiang Chen, </li><li class="list-inline-item cited-by__entry__author">Qian Yang, </li><li class="list-inline-item cited-by__entry__author">Siming Zhang, </li><li class="list-inline-item cited-by__entry__author">Fang Liu, </li><li class="list-inline-item cited-by__entry__author">Ying Chen, </li><li class="list-inline-item cited-by__entry__author">Liyan Zhang, </li><li class="list-inline-item cited-by__entry__author">Chengda Zhang, </li><li class="list-inline-item cited-by__entry__author">Wanqiang Lv, </li><li class="list-inline-item cited-by__entry__author">Enqi Huang, </li><li class="list-inline-item cited-by__entry__author">Lijiang Zhang, </li></ul><span class="cited-by__entry__title">Repeated-dose toxicity and immunogenicity evaluation of a recombinant subunit COVID-19 vaccine (ZF2001) in rats, </span><span class="cited-by__entry__series-title">Frontiers in Cellular and Infection Microbiology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fcimb.2025.1548787" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fcimb.2025.1548787</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fcimb.2025.1548787" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Runping Su, </li><li class="list-inline-item cited-by__entry__author">Tingting Yao, </li><li class="list-inline-item cited-by__entry__author">Chong Cao, </li><li class="list-inline-item cited-by__entry__author">Yaqi Yang, </li><li class="list-inline-item cited-by__entry__author">Mingshan Chen, </li><li class="list-inline-item cited-by__entry__author">Jianxiao Wu, </li><li class="list-inline-item cited-by__entry__author">Yue Zhao, </li><li class="list-inline-item cited-by__entry__author">Xiaoxiao Liu, </li><li class="list-inline-item cited-by__entry__author">Sha Li, </li><li class="list-inline-item cited-by__entry__author">Junqiang Ding, </li><li class="list-inline-item cited-by__entry__author">Rong Yang, </li><li class="list-inline-item cited-by__entry__author">Shun Shen, </li><li class="list-inline-item cited-by__entry__author">Chuan Zhang, </li><li class="list-inline-item cited-by__entry__author">Changyou Zhan, </li><li class="list-inline-item cited-by__entry__author">Xihui Gao, </li></ul><span class="cited-by__entry__title">Enhancing Immune Responses Through Modulation of Innate Cell Microenvironments in Lymph Nodes with Virus‐Mimetic Vaccines, </span><span class="cited-by__entry__series-title">Angewandte Chemie International Edition, </span><span class="cited-by__entry__volume"><strong>64</strong>, </span><span class="cited-by__entry__issue">21, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/anie.202503845" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/anie.202503845</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/anie.202503845" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-22%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2202261" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2202261" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2202261" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2202261.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f1.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/afe6bc88-4dd6-402a-bd8c-2c2b4c01a8d6/assets/images/large/nejmoa2202261_f1.jpg" height="2990" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, Follow-up, and Analyses Performed up to the Second Data Cutoff Date of December 15, 2021.</div><div class="notes"><div role="doc-footnote">Eight participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group in the safety analysis. Covid-19 denotes coronavirus disease 2019.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f2.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/60565818-8d32-42d9-970e-ad174ee0ba13/assets/images/large/nejmoa2202261_f2.jpg" height="1932" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Plots of the Cumulative Incidence of Symptomatic Covid-19 in the Trial Groups.</div><div class="notes"><div role="doc-footnote">The cumulative incidence of symptomatic Covid-19, as confirmed on real-time polymerase-chain-reaction (PCR) assay, with an onset of at least 7 days after the third dose of ZF2001 or placebo (the primary end point) in the modified full analysis set for efficacy is shown at the first data cutoff date of June 30, 2021 (Panel A) and at the second data cutoff date of December 15, 2021 (Panel B). The cumulative incidence of real-time PCR–confirmed symptomatic Covid-19, with an onset after the first dose of ZF2001 or placebo, in the full analysis set for efficacy is shown at the first data cutoff date of June 30, 2021 (Panel C) and at the second data cutoff date of December 15, 2021 (Panel D). In each panel, the inset shows the same data on an enlarged y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f3.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/7120cef1-8a66-4a6d-bc0f-d9322de9b038/assets/images/large/nejmoa2202261_f3.jpg" height="2664" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Adverse Events at the Second Data Cutoff Date of December 15, 2021.</div><div class="notes"><div role="doc-footnote">Panel A shows the incidence of adverse events, both overall and according to age group, among the participants who received at least one dose of ZF2001 or placebo. Panel B shows the overall incidence of local and systemic adverse reactions. A total of 28,873 participants were included in the safety analysis set (14,448 in the ZF2001 group and 14,425 in the placebo group); 8 participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group for the safety analysis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2202261/asset/efad7c94-7163-4f5b-a15c-55247858575c/assets/images/large/nejmoa2202261_t1.jpg" height="2545" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Characteristic</th><th class="xxxx-borders">ZF2001<br>(N=14,453)<a href="#core-t1fn2" role="doc-noteref">†</a></th><th class="xxxx-borders">Placebo<br>(N=14,451)<a href="#core-t1fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">All Participants<br>(N=28,904)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">37.0±13.1</td><td class="xxxx-borders shading">36.7±13.1</td><td class="xxxx-borders shading">36.8±13.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">35.0 (18–92)</td><td class="xxxx-borders">35.0 (17–88)</td><td class="xxxx-borders">35.0 (17–92)</td></tr><tr data-type="row"><td class="xxxx-borders hanging14 shading">Distribution</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24" data-xml-align="left">18–59 yr — no. (%)</td><td class="xxxx-borders">13,534 (93.6)</td><td class="xxxx-borders">13,531 (93.6)</td><td class="xxxx-borders">27,065 (93.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34 shading" data-xml-align="left">Mean — yr</td><td class="xxxx-borders shading">35.0±11.0</td><td class="xxxx-borders shading">34.7±10.9</td><td class="xxxx-borders shading">34.8±10.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">34.0 (18–59)</td><td class="xxxx-borders">34.0 (17–59)</td><td class="xxxx-borders">34.0 (17–59)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24 shading" data-xml-align="left">≥60 yr</td><td class="xxxx-borders shading">919 (6.4)</td><td class="xxxx-borders shading">920 (6.4)</td><td class="xxxx-borders shading">1,839 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">66.2±5.6</td><td class="xxxx-borders">65.8±5.0</td><td class="xxxx-borders">66.0±5.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging34 shading" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders shading">65.0 (60–92)</td><td class="xxxx-borders shading">65.0 (60–88)</td><td class="xxxx-borders shading">65.0 (60–92)</td></tr><tr data-type="row"><td class="xxxx-borders hanging04">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">9,766 (67.6)</td><td class="xxxx-borders shading">9,755 (67.5)</td><td class="xxxx-borders shading">19,521 (67.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Female</td><td class="xxxx-borders">4,687 (32.4)</td><td class="xxxx-borders">4,696 (32.5)</td><td class="xxxx-borders">9,383 (32.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging04 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">25.53±4.7</td><td class="xxxx-borders shading">25.55±4.7</td><td class="xxxx-borders shading">25.54±4.7</td></tr><tr data-type="row"><td class="xxxx-borders hanging04">Race or ethnic group — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Ethnic Chinese</td><td class="xxxx-borders shading">503 (3.5)</td><td class="xxxx-borders shading">503 (3.5)</td><td class="xxxx-borders shading">1,006 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Asian but not ethnic Chinese</td><td class="xxxx-borders">11,251 (77.8)</td><td class="xxxx-borders">11,225 (77.7)</td><td class="xxxx-borders">22,476 (77.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Black or African or Caribbean</td><td class="xxxx-borders shading">5 (&lt;0.1)</td><td class="xxxx-borders shading">8 (&lt;0.1)</td><td class="xxxx-borders shading">13 (&lt;0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">White</td><td class="xxxx-borders">41 (0.3)</td><td class="xxxx-borders">59 (0.4)</td><td class="xxxx-borders">100 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Multiracial</td><td class="xxxx-borders shading">2,650 (18.3)</td><td class="xxxx-borders shading">2,655 (18.4)</td><td class="xxxx-borders shading">5,305 (18.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Other</td><td class="xxxx-borders">3 (&lt;0.1)</td><td class="xxxx-borders">1 (&lt;0.1)</td><td class="xxxx-borders">4 (&lt;0.1)</td></tr><tr data-type="row"><td class="xxxx-borders hanging04 shading">SARS-CoV-2 status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Positive for IgG, IgM, or antigen or had positive real-time PCR assay<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">3 (&lt;0.1)</td><td class="xxxx-borders">4 (&lt;0.1)</td><td class="xxxx-borders">7 (&lt;0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14 shading" data-xml-align="left">Negative for IgG, IgM, and antigen and had negative real-time PCR assay</td><td class="xxxx-borders shading">14,437 (99.9)</td><td class="xxxx-borders shading">14,429 (99.8)</td><td class="xxxx-borders shading">28,866 (99.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging14" data-xml-align="left">Data missing</td><td class="xxxx-borders">13 (&lt;0.1)</td><td class="xxxx-borders">18 (0.1)</td><td class="xxxx-borders">31 (0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging04 shading" data-xml-align="left">Any coexisting medical condition — no. (%)<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">1,904 (13.2)</td><td class="xxxx-borders shading">1,925 (13.3)</td><td class="xxxx-borders shading">3,829 (13.2)</td></tr><tr data-type="row"><td class="xxxx-borders hanging14">Distribution according to age group</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24 shading" data-xml-align="left">18–59 yr</td><td class="xxxx-borders shading">1,601 (11.1)</td><td class="xxxx-borders shading">1,617 (11.2)</td><td class="xxxx-borders shading">3,218 (11.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging24" data-xml-align="left">≥60 yr</td><td class="xxxx-borders">303 (2.1)</td><td class="xxxx-borders">308 (2.1)</td><td class="xxxx-borders">611 (2.1)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. PCR denotes polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Among the participants who had been randomly assigned to receive ZF2001, placebo was incorrectly administered to 8 at the first dose, 9 at the second dose, and 4 at the third dose. These participants were included in the protocol violation report.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Among the participants who had been randomly assigned to receive placebo, ZF2001 was incorrectly administered to 4 at the first dose, 3 at the second dose, and 3 at the third dose. These participants were included in the protocol violation report.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Race or ethnic group was reported by the participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Seven participants who were positive for IgG or IgM antibodies or SARS-CoV-2 antigen or had a positive real-time PCR assay at baseline were recruited by the site investigators in error. These participants were included in the protocol violation report.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Coexisting medical conditions were diseases that had started before the first dose and ended after the first dose or persisted during the trial. Coexisting conditions were classified according to the <i>Medical Dictionary for Regulatory Activities</i>, version 24.0.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Intention-to-Treat Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2202261/asset/28baa0e7-0af5-4182-9d5b-bdd50505a150/assets/images/large/nejmoa2202261_t2.jpg" height="2832" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Efficacy Analysis</th><th class="txxx-borders" colspan="4"><span>At First Data Cutoff: June 30, 2021</span></th><th class="txxr-borders" colspan="4"><span>At Second Data Cutoff: Dec. 15, 2021</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total Cases</th><th class="xxxx-borders">ZF2001</th><th class="xxxx-borders">Placebo</th><th class="xxxx-borders">Vaccine Efficacy<br>(95% CI)</th><th class="xxxx-borders">Total Cases</th><th class="xxxx-borders">ZF2001</th><th class="xxxx-borders">Placebo</th><th class="xxxr-borders">Vaccine Efficacy<br>(95% CI)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no.</th><th class="xxxx-borders" colspan="2"><span>no. of cases/no. at risk</span></th><th class="xxxx-borders">%</th><th class="xxxx-borders">no.</th><th class="xxxx-borders" colspan="2"><span>no. of cases/no. at risk</span></th><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Analyses in the modified full analysis set</b><a href="#core-t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Primary end point: symptomatic Covid-19 occurring ≥7 days after the third dose</td><td class="xxxx-borders">224</td><td class="xxxx-borders">36/7359</td><td class="xxxx-borders">188/7322</td><td class="xxxx-borders">81.4 (73.3 to 87.3)</td><td class="xxxx-borders">738</td><td class="xxxx-borders">158/12,625</td><td class="xxxx-borders">580/12,568</td><td class="xxxr-borders">75.7 (71.0 to 79.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Secondary end point: severe-to-critical Covid-19 occurring ≥7 days after the third dose</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">1/7359</td><td class="xxxx-borders shading">13/7322</td><td class="xxxx-borders shading">92.9 (52.4 to 99.8)</td><td class="xxxx-borders shading">49</td><td class="xxxx-borders shading">6/12,656</td><td class="xxxx-borders shading">43/12,568</td><td class="xxxr-borders shading">87.6 (70.6 to 95.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Secondary end-point component: Covid-19–related death occurring ≥7 days after the third dose</td><td class="xxxx-borders">5</td><td class="xxxx-borders">0/7359</td><td class="xxxx-borders">5/7322</td><td class="xxxx-borders">100 (−8.4 to 100)</td><td class="xxxx-borders">14</td><td class="xxxx-borders">2/12,656</td><td class="xxxx-borders">12/12,568</td><td class="xxxr-borders">86.5 (38.9 to 98.5)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><b>Subgroup analyses in the modified full analysis set</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders">Analysis according to age</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">18–59 yr</td><td class="xxxx-borders shading">216</td><td class="xxxx-borders shading">35/7153</td><td class="xxxx-borders shading">181/7111</td><td class="xxxx-borders shading">81.2 (72.8 to 87.3)</td><td class="xxxx-borders shading">710</td><td class="xxxx-borders shading">150/11,921</td><td class="xxxx-borders shading">560/11,846</td><td class="xxxr-borders shading">76.0 (71.2 to 80.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥60 yr</td><td class="xxxx-borders">8</td><td class="xxxx-borders">1/206</td><td class="xxxx-borders">7/211</td><td class="xxxx-borders">87.6 (2.5 to 99.7)</td><td class="xxxx-borders">28</td><td class="xxxx-borders">8/704</td><td class="xxxx-borders">20/722</td><td class="xxxr-borders">67.6 (21.9 to 87.8)</td></tr><tr data-type="row"><td class="xxlx-borders shading">Analysis according to country<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Uzbekistan</td><td class="xxxx-borders">53</td><td class="xxxx-borders">7/3185</td><td class="xxxx-borders">46/3180</td><td class="xxxx-borders">84.8 (66.2 to 94.2)</td><td class="xxxx-borders">191</td><td class="xxxx-borders">35/3226</td><td class="xxxx-borders">156/3221</td><td class="xxxr-borders">80.2 (71.3 to 86.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Indonesia</td><td class="xxxx-borders shading">159</td><td class="xxxx-borders shading">28/1908</td><td class="xxxx-borders shading">131/1895</td><td class="xxxx-borders shading">79.4 (68.9 to 86.9)</td><td class="xxxx-borders shading">352</td><td class="xxxx-borders shading">77/1927</td><td class="xxxx-borders shading">275/1902</td><td class="xxxr-borders shading">76.0 (68.9 to 81.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Ecuador</td><td class="xxxx-borders">12</td><td class="xxxx-borders">1/1323</td><td class="xxxx-borders">11/1293</td><td class="xxxx-borders">91.2 (39.5 to 99.8)</td><td class="xxxx-borders">130</td><td class="xxxx-borders">33/2280</td><td class="xxxx-borders">97/2249</td><td class="xxxr-borders">67.6 (51.4 to 78.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pakistan</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0/943</td><td class="xxxx-borders shading">0/954</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">13/5192</td><td class="xxxx-borders shading">52/5196</td><td class="xxxr-borders shading">75.1 (53.7 to 87.6)</td></tr><tr data-type="row"><td class="xxlx-borders">Analysis according to race</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">211</td><td class="xxxx-borders shading">35/5997</td><td class="xxxx-borders shading">176/5964</td><td class="xxxx-borders shading">80.7 (72.1 to 87.0)</td><td class="xxxx-borders shading">601</td><td class="xxxx-borders shading">124/10,303</td><td class="xxxx-borders shading">477/10,252</td><td class="xxxr-borders shading">77.2 (72.2 to 81.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other race</td><td class="xxxx-borders">13</td><td class="xxxx-borders">1/1362</td><td class="xxxx-borders">12/1358</td><td class="xxxx-borders">91.7 (43.4 to 99.8)</td><td class="xxxx-borders">137</td><td class="xxxx-borders">34/2322</td><td class="xxxx-borders">103/2316</td><td class="xxxr-borders">68.2 (52.8 to 79.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Analysis according to coexisting conditions that were risk factors for severe Covid-19</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cardiovascular disease</td><td class="xxxx-borders">12</td><td class="xxxx-borders">1/203</td><td class="xxxx-borders">11/242</td><td class="xxxx-borders">93.1 (45.4 to 99.9)</td><td class="xxxx-borders">38</td><td class="xxxx-borders">11/401</td><td class="xxxx-borders">27/454</td><td class="xxxr-borders">64.0 (20.2 to 84.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diabetes</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">1/88</td><td class="xxxx-borders shading">4/95</td><td class="xxxx-borders shading">31.7 (−1264.8 to 98.9)</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">5/279</td><td class="xxxx-borders shading">12/299</td><td class="xxxr-borders shading">55.4 (−60.4 to 90.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Chronic lung disease</td><td class="xxxx-borders">3</td><td class="xxxx-borders">1/42</td><td class="xxxx-borders">2/27</td><td class="xxxx-borders">74.0 (−435.3 to 99.6)</td><td class="xxxx-borders">7</td><td class="xxxx-borders">2/54</td><td class="xxxx-borders">5/43</td><td class="xxxr-borders">86.7 (−13.9 to 99.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Severe obesity</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0/8</td><td class="xxxx-borders shading">1/11</td><td class="xxxx-borders shading">100 (−3275.7 to 100)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0/9</td><td class="xxxx-borders shading">1/14</td><td class="xxxr-borders shading">100 (−4353.8 to 100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any of the above</td><td class="xxxx-borders">19</td><td class="xxxx-borders">3/308</td><td class="xxxx-borders">16/344</td><td class="xxxx-borders">84.4 (41.9 to 97.2)</td><td class="xxxx-borders">58</td><td class="xxxx-borders">18/661</td><td class="xxxx-borders">40/716</td><td class="xxxr-borders">61.6 (29.5 to 79.9)</td></tr><tr data-type="row"><td class="xxlx-borders shading">Analysis according to SARS-CoV-2 variant<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">B.1.617.2, AY.4, AY.6, or AY.12 (delta)</td><td class="xxxx-borders">130</td><td class="xxxx-borders">21/7359</td><td class="xxxx-borders">109/7322</td><td class="xxxx-borders">81.4 (70.1 to 88.9)</td><td class="xxxx-borders">454</td><td class="xxxx-borders">96/12,625</td><td class="xxxx-borders">358/12,568</td><td class="xxxr-borders">76.1 (70.0 to 81.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">B.1.1.7 (alpha)</td><td class="xxxx-borders shading">29</td><td class="xxxx-borders shading">2/7359</td><td class="xxxx-borders shading">27/7322</td><td class="xxxx-borders shading">92.7 (70.9 to 99.2)</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">4/12,625</td><td class="xxxx-borders shading">31/12,568</td><td class="xxxr-borders shading">88.3 (66.8 to 97.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">B.1.617.1 (kappa) or B.1.617.3</td><td class="xxxx-borders">15</td><td class="xxxx-borders">2/7359</td><td class="xxxx-borders">13/7322</td><td class="xxxx-borders">84.8 (32.9 to 98.3)</td><td class="xxxx-borders">68</td><td class="xxxx-borders">15/12,625</td><td class="xxxx-borders">53/12,568</td><td class="xxxr-borders">75.2 (55.3 to 87.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other variants or not identified<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">50</td><td class="xxxx-borders shading">11/7359</td><td class="xxxx-borders shading">38/7322</td><td class="xxxx-borders shading">71.3 (42.7 to 86.8)</td><td class="xxxx-borders shading">181</td><td class="xxxx-borders shading">43/12,625</td><td class="xxxx-borders shading">138/12,568</td><td class="xxxr-borders shading">71.9 (60.1 to 80.5)</td></tr><tr data-type="row"><td class="xxlx-borders"><b>Analyses in the full analysis set</b><a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Symptomatic Covid-19 since the first dose</td><td class="xxxx-borders shading">663</td><td class="xxxx-borders shading">249/13,669</td><td class="xxxx-borders shading">414/13,664</td><td class="xxxx-borders shading">40.2 (29.9 to 49.1)</td><td class="xxxx-borders shading">1255</td><td class="xxxx-borders shading">405/13,909</td><td class="xxxx-borders shading">850/13,899</td><td class="xxxr-borders shading">55.4 (49.7 to 60.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Severe-to-critical Covid-19 since the first dose</td><td class="xxxx-borders">59</td><td class="xxxx-borders">26/13,669</td><td class="xxxx-borders">33/13,664</td><td class="xxxx-borders">21.6 (−35.1 to 55.0)</td><td class="xxxx-borders">101</td><td class="xxxx-borders">36/13,909</td><td class="xxxx-borders">65/13,899</td><td class="xxxr-borders">47.4 (19.8 to 66.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders shading" data-xml-align="left">Covid-19–related death since the first dose</td><td class="xbxx-borders shading">6</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">6/13,664</td><td class="xbxx-borders shading">100 (15.2 to 100)</td><td class="xbxx-borders shading">18</td><td class="xbxx-borders shading">4/13,909</td><td class="xbxx-borders shading">14/13,898</td><td class="xbxr-borders shading">75.5 (21.5 to 94.1)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"><div class="label">*</div></a><div id="core-t2fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg">The modified full analysis set for efficacy included all the participants who had undergone randomization and completed the three-dose regimen (additional exclusion criteria are listed in Table S3 in the </a><a href="#ap2">Supplementary Appendix</a>). Participants who had received the incorrect trial regimen were included in the analysis according to their trial-group assignment on the basis of the intention-to-treat principle. Covid-19 denotes coronavirus disease 2019, and NA not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Lot 1 vaccine was used in the Uzbekistan cohort, and lot 2 vaccine was used in the other countries.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Vaccine efficacy against each severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant was determined on the basis of symptomatic cases in the modified full analysis set for efficacy that were confirmed on real-time PCR assay and had SARS-CoV-2 genotyped with nasopharyngeal swabs.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Nasopharyngeal swabs with a cycle threshold value of 30 or more were not genotyped. We were able to retrieve sequences or genotypes from 185 case samples in the short-term follow-up and 626 case samples in the long-term follow-up. Shown are the efficacies against three major variants. The other 11 confirmed SARS-CoV-2 variants identified in the short-term follow-up and 69 in the long-term follow-up are shown in Table S14.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">The full analysis set for efficacy included all the participants who had undergone randomization and received at least one dose of vaccine or placebo. The full analysis set was used to evaluate protective efficacy after the first dose. The end-point cases were counted since the receipt of the first dose of vaccine or placebo. The current analysis did not include data from 7 participants who had a positive test for IgG or IgM antibodies or SARS-CoV-2 antigen or had a positive real-time PCR assay at baseline and those who had not yet completed at least one case-surveillance follow-up visit (121 patients at the first data cutoff date and 27 at the second data cutoff date).</div></div></div></figcaption><figcaption><div class="caption">Vaccine Efficacy of ZF2001 against Covid-19 According to Analysis Groups.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202261_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2202261</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Gao GF. Science-based COVID-19 vaccine development. <em>Natl Sci Rev</em> 2021;8:nwab193-nwab193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nsr/nwab193" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34858619/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000720750500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Science-based+COVID-19+vaccine+development.&amp;publication_year=2021&amp;journal=Natl+Sci+Rev&amp;pages=nwab193-nwab193&amp;doi=10.1093%2Fnsr%2Fnwab193&amp;pmid=34858619" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Dai L, Gao GF. Viral targets for vaccines against COVID-19. <em>Nat Rev Immunol</em> 2021;21:73-82.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41577-020-00480-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33340022/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000600085200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Viral+targets+for+vaccines+against+COVID-19.&amp;publication_year=2021&amp;journal=Nat+Rev+Immunol&amp;pages=73-82&amp;doi=10.1038%2Fs41577-020-00480-0&amp;pmid=33340022" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the cornerstone of pandemic control. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the currently approved Covid-19 vaccines. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] with receptor-binding activities. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">COVID-19 vaccine tracker. Approved vaccines (<a href="https://covid19.trackvaccines.org/vaccines/approved">https://covid19.trackvaccines.org/vaccines/approved</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=COVID-19+vaccine+tracker.+Approved+vaccines+%28https%3A%2F%2Fcovid19.trackvaccines.org%2Fvaccines%2Fapproved%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the cornerstone of pandemic control. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] are in late stages of clinical trials </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] China, Uzbekistan, Indonesia, and Colombia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in late stages of clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. <em>JAMA</em> 2021;326:35-45.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2021.8565" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34037666/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000655672100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+2+inactivated+SARS-CoV-2+vaccines+on+symptomatic+COVID-19+infection+in+adults%3A+a+randomized+clinical+trial.&amp;publication_year=2021&amp;journal=JAMA&amp;pages=35-45&amp;doi=10.1001%2Fjama.2021.8565&amp;pmid=34037666" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. <em>Lancet</em> 2021;398:2173-2184.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)02000-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34774196/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000729467800005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+lot-to-lot+immunogenicity+of+an+inactivated+SARS-CoV-2+vaccine+%28BBV152%29%3A+interim+results+of+a+randomised%2C+double-blind%2C+controlled%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=2173-2184&amp;doi=10.1016%2FS0140-6736%2821%2902000-6&amp;pmid=34774196" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] was shown to have an efficacy of 65.2%, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for two vaccines (BBV152 and SCB-2019). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <em>Lancet Infect Dis</em> 2022;22:329-340.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(21)00677-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34826381/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000762437600028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+the+CVnCoV+SARS-CoV-2+mRNA+vaccine+candidate+in+ten+countries+in+Europe+and+Latin+America+%28HERALD%29%3A+a+randomised%2C+observer-blinded%2C+placebo-controlled%2C+phase+2b%2F3+trial.&amp;publication_year=2022&amp;journal=Lancet+Infect+Dis&amp;pages=329-340&amp;doi=10.1016%2FS1473-3099%2821%2900677-0&amp;pmid=34826381" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and CVnCoV an efficacy of 55.1%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. <em>Lancet</em> 2021;397:671-681.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00234-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33545094/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000620991800029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+an+rAd26+and+rAd5+vector-based+heterologous+prime-boost+COVID-19+vaccine%3A+an+interim+analysis+of+a+randomised+controlled+phase+3+trial+in+Russia.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=671-681&amp;doi=10.1016%2FS0140-6736%2821%2900234-8&amp;pmid=33545094" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. <em>N Engl J Med</em> 2021;384:403-416.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2035389&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33378609/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000629333200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+the+mRNA-1273+SARS-CoV-2+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=403-416&amp;doi=10.1056%2FNEJMoa2035389&amp;pmid=33378609" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] shown to have an efficacy of 90 to 96%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. <em>N Engl J Med</em> 2022;386:531-543.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2116185&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34910859/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000730408900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+NVX-CoV2373+in+adults+in+the+United+States+and+Mexico.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=531-543&amp;doi=10.1056%2FNEJMoa2116185&amp;pmid=34910859" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] shown to have an efficacy of 90 to 96%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] NVX-CoV2373 showed an efficacy of 93.6% </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. <em>N Engl J Med</em> 2021;385:2348-2360.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2105290&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34587382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000701157100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+3+safety+and+efficacy+of+AZD1222+%28ChAdOx1+nCoV-19%29+Covid-19+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2348-2360&amp;doi=10.1056%2FNEJMoa2105290&amp;pmid=34587382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. <em>N Engl J Med</em> 2021;385:1172-1183.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2107659&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34192426/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000669588900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+NVX-CoV2373+Covid-19+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1172-1183&amp;doi=10.1056%2FNEJMoa2107659&amp;pmid=34192426" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. <em>N Engl J Med</em> 2021;384:2187-2201.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_13_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2101544&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33882225/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000642260000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+single-dose+Ad26.COV2.S+vaccine+against+Covid-19.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2187-2201&amp;doi=10.1056%2FNEJMoa2101544&amp;pmid=33882225" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in a phase 2 clinical trial of ZF2001. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. <em>N Engl J Med</em> 2020;383:2603-2615.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_14_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2034577&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33301246/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605648000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2603-2615&amp;doi=10.1056%2FNEJMoa2034577&amp;pmid=33301246" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] shown to have an efficacy of 90 to 96%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. <em>Lancet</em> 2022;399:237-248.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)02753-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34953526/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000746041700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Final+efficacy+analysis%2C+interim+safety+analysis%2C+and+immunogenicity+of+a+single+dose+of+recombinant+novel+coronavirus+vaccine+%28adenovirus+type+5+vector%29+in+adults+18+years+and+older%3A+an+international%2C+multicentre%2C+randomised%2C+double-blinded%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2022&amp;journal=Lancet&amp;pages=237-248&amp;doi=10.1016%2FS0140-6736%2821%2902753-7&amp;pmid=34953526" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. <em>Lancet</em> 2022;399:461-472.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(22)00055-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35065705/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000755141600026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+adjuvanted+subunit+protein+COVID-19+vaccine%2C+SCB-2019%3A+a+phase+2+and+3+multicentre%2C+double-blind%2C+randomised%2C+placebo-controlled+trial.&amp;publication_year=2022&amp;journal=Lancet&amp;pages=461-472&amp;doi=10.1016%2FS0140-6736%2822%2900055-1&amp;pmid=35065705" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on different platforms have been reported, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] was shown to have an efficacy of 78.7%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for two vaccines (BBV152 and SCB-2019). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">COVID-19 vaccine tracker and landscape. Geneva: World Health Organization, March 29, 2022 (<a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=COVID-19+vaccine+tracker+and+landscape.+Geneva%3A+World+Health+Organization%2C+March+29%2C+2022+%28https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fdraft-landscape-of-covid-19-candidate-vaccines%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] are in late stages of clinical trials </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in late stages of clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. <em>Nature</em> 2021;600:408-418.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-021-04188-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34880490/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000728552800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+emergence%2C+genomic+diversity+and+global+spread+of+SARS-CoV-2.&amp;publication_year=2021&amp;journal=Nature&amp;pages=408-418&amp;doi=10.1038%2Fs41586-021-04188-6&amp;pmid=34880490" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Pormohammad A, Zarei M, Ghorbani S, et al. Effectiveness of COVID-19 vaccines against delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies. <em>Vaccines (Basel)</em> 2021;10:23-23.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3390/vaccines10010023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35062684/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000761990100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+COVID-19+vaccines+against+delta+%28B.1.617.2%29+variant%3A+a+systematic+review+and+meta-analysis+of+clinical+studies.&amp;publication_year=2021&amp;journal=Vaccines+%28Basel%29&amp;pages=23-23&amp;doi=10.3390%2Fvaccines10010023&amp;pmid=35062684" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. <em>Cell</em> 2020;182(3):722-733.e11.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.06.035" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32645327/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000558649000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+universal+design+of+betacoronavirus+vaccines+against+COVID-19%2C+MERS%2C+and+SARS.&amp;publication_year=2020&amp;journal=Cell&amp;pages=722-733.e11&amp;doi=10.1016%2Fj.cell.2020.06.035&amp;pmid=32645327" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">An Y, Li S, Jin X, et al. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. <em>Emerg Microbes Infect</em> 2022;11:1058-1071.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35311493/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+tandem-repeat+dimeric+RBD+protein-based+covid-19+vaccine+zf2001+protects+mice+and+nonhuman+primates.&amp;publication_year=2022&amp;pages=1058-1071&amp;pmid=35311493" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <em>Lancet Infect Dis</em> 2021;21:1107-1119.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(21)00127-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33773111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000680046200042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+recombinant+tandem-repeat+dimeric+RBD-based+protein+subunit+vaccine+%28ZF2001%29+against+COVID-19+in+adults%3A+two+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+1+and+2+trials.&amp;publication_year=2021&amp;journal=Lancet+Infect+Dis&amp;pages=1107-1119&amp;doi=10.1016%2FS1473-3099%2821%2900127-4&amp;pmid=33773111" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] was selected for use in a phase 3 trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] phase 1 and 2 trials in smaller cohorts. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Huang B, Dai L, Wang H, et al. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. <em>Lancet Microbe</em> 2021;2(7):e285-e285.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2666-5247(21)00082-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33870240/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Serum+sample+neutralisation+of+BBIBP-CorV+and+ZF2001+vaccines+to+SARS-CoV-2+501Y.V2.&amp;publication_year=2021&amp;journal=Lancet+Microbe&amp;pages=e285-e285&amp;doi=10.1016%2FS2666-5247%2821%2900082-3&amp;pmid=33870240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Zhao X, Zheng A, Li D, et al. Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. <em>Lancet Microbe</em> 2021;2(10):e494-e494.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2666-5247(21)00217-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34458880/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neutralisation+of+ZF2001-elicited+antisera+to+SARS-CoV-2+variants.&amp;publication_year=2021&amp;journal=Lancet+Microbe&amp;pages=e494-e494&amp;doi=10.1016%2FS2666-5247%2821%2900217-2&amp;pmid=34458880" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] delta, B.1.617.1 (kappa), and omicron, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] use of a pseudovirus neutralization assay. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Zhao X, Li D, Ruan W, et al. Effects of a prolonged booster interval on neutralization of omicron variant. <em>N Engl J Med</em> 2022;386:894-896.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_25_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMc2119426&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35081296/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000747075500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+a+prolonged+booster+interval+on+neutralization+of+omicron+variant.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=894-896&amp;doi=10.1056%2FNEJMc2119426&amp;pmid=35081296" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] delta, B.1.617.1 (kappa), and omicron, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] use of a pseudovirus neutralization assay. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">An international randomised trial of candidate vaccines against COVID-19. Geneva: World Health Organization, May 28, 2020 (<a href="https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19">https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=An+international+randomised+trial+of+candidate+vaccines+against+COVID-19.+Geneva%3A+World+Health+Organization%2C+May+28%2C+2020+%28https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fan-international-randomised-trial-of-candidate-vaccines-against-covid-19%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Design of vaccine efficacy trials to be used during public health emergencies — points of considerations and key principles. Geneva: World Health Organization, 2019 (<a href="https://www.who.int/docs/default-source/blue-print/working-group-for-vaccine-evaluation-(4th-consultation)/ap1-guidelines-online-consultation.pdf">https://www.who.int/docs/default-source/blue-print/working-group-for-vaccine-evaluation-(4th-consultation)/ap1-guidelines-online-consultation.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Design+of+vaccine+efficacy+trials+to+be+used+during+public+health+emergencies+%E2%80%94+points+of+considerations+and+key+principles.+Geneva%3A+World+Health+Organization%2C+2019+%28https%3A%2F%2Fwww.who.int%2Fdocs%2Fdefault-source%2Fblue-print%2Fworking-group-for-vaccine-evaluation-%284th-consultation%29%2Fap1-guidelines-online-consultation.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. <em>Commun Stat Theory Methods</em> 1998;27:1305-1322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03610929808832160" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000073860500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Exact+power+and+sample+size+for+vaccine+efficacy+studies.&amp;publication_year=1998&amp;journal=Commun+Stat+Theory+Methods&amp;pages=1305-1322&amp;doi=10.1080%2F03610929808832160" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. <em>Biometrics</em> 1979;35:549-556.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2307/2530245" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/497341/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1979HM72500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multiple+testing+procedure+for+clinical+trials.&amp;publication_year=1979&amp;journal=Biometrics&amp;pages=549-556&amp;doi=10.2307%2F2530245&amp;pmid=497341" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Kleanthous H, Silverman JM, Makar KW, Yoon IK, Jackson N, Vaughn DW. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <em>NPJ Vaccines</em> 2021;6:128-128.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41541-021-00393-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34711846/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000712410100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Scientific+rationale+for+developing+potent+RBD-based+vaccines+targeting+COVID-19.&amp;publication_year=2021&amp;journal=NPJ+Vaccines&amp;pages=128-128&amp;doi=10.1038%2Fs41541-021-00393-6&amp;pmid=34711846" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">WHO target product profiles for COVID-19 vaccines. Geneva: World Health Organization, April 9, 2020 (<a href="https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines">https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=WHO+target+product+profiles+for+COVID-19+vaccines.+Geneva%3A+World+Health+Organization%2C+April+9%2C+2020+%28https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fwho-target-product-profiles-for-covid-19-vaccines%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. <em>N Engl J Med</em> 2021;385:585-594.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_32_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202261&amp;key=10.1056%2FNEJMoa2108891&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34289274/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000675554200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+Covid-19+vaccines+against+the+B.1.617.2+%28delta%29+variant.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=585-594&amp;doi=10.1056%2FNEJMoa2108891&amp;pmid=34289274" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <em>BMJ</em> 2021;375:e068848-e068848.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34911691/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000732451800013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+mRNA-1273+against+delta%2C+mu%2C+and+other+emerging+variants+of+SARS-CoV-2%3A+test+negative+case-control+study.&amp;publication_year=2021&amp;journal=BMJ&amp;pages=e068848-e068848&amp;pmid=34911691" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar. <em>Nat Med</em> 2021;27:2136-2143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-021-01583-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34728831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000713960400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+and+mRNA-1273+COVID-19+vaccine+effectiveness+against+the+SARS-CoV-2+delta+variant+in+Qatar.&amp;publication_year=2021&amp;journal=Nat+Med&amp;pages=2136-2143&amp;doi=10.1038%2Fs41591-021-01583-4&amp;pmid=34728831" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. <em>Plotkin’s vaccines. 7th ed</em>. Philadelphia: Elsevier, 2018:342-374.e17.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/B978-0-323-35761-6.00025-0" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hepatitis+B+vaccines&amp;publication_year=2018&amp;pages=342-374.e17&amp;doi=10.1016%2FB978-0-323-35761-6.00025-0" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. <em>Plotkin’s vaccines. 7th ed</em>. Philadelphia: Elsevier, 2018:430-455.e10.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/B978-0-323-35761-6.00030-4" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+vaccines&amp;publication_year=2018&amp;pages=430-455.e10&amp;doi=10.1016%2FB978-0-323-35761-6.00030-4" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 04, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2201300" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">K.J. Hager and Others</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 04, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2204695" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Does the World Still Need New Covid-19 Vaccines?</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H. Nohynek and A. Wilder-Smith</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/726364/gastroenterology-south-shore-university-hospital/?query=fjwp&amp;rid=3059">Gastroenterology - South Shore University Hospital</a></div></div><div class="nejm-widget_item"><div><span> Loma Linda, California</span></div><div><span>Ophthalmology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883949/academic-neuro-ophthalmologist-opportunity-in-southern-california/?query=fjwp&amp;rid=69418">Academic Neuro-Ophthalmologist Opportunity in Southern California</a></div></div><div class="nejm-widget_item"><div><span> East Providence, Rhode Island</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879432/adult-psychiatrist/?query=fjwf&amp;rid=377088">Adult Psychiatrist</a></div></div><div class="nejm-widget_item"><div><span> Scranton, Pennsylvania</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890157/physician-orthopaedic-surgery-hand/?query=fjwf&amp;rid=764">Physician Orthopaedic Surgery Hand</a></div></div><div class="nejm-widget_item"><div><span> Akron, Ohio</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885074/optum-unity-health-network-primary-care-physician-akron-oh/?query=fjwf&amp;rid=220874">Optum Unity Health Network Primary Care Physician - Akron, OH</a></div></div><div class="nejm-widget_item"><div><span> Eugene, Oregon</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879544/family-medicine/?query=fjwf&amp;rid=14710">Family Medicine</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2202261&amp;pubId=41283775&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6d4f893d13289-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6d4f893d13289-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6d4f893d13289-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$067074646$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$067074646$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$067074646$--></div></div><div class="mlt-body"><!--?lit$067074646$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$067074646$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$067074646$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$067074646$-->Jun 10, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105000?query=recirc_Semantic" target="_self">Brief Report: Vaccine Breakthrough Infections with SARS-CoV-2 Variants</a></div><div class="mlt-article-authors"><!--?lit$067074646$-->E. Hacisuleyman and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/special-report" target="_self"><!--?lit$067074646$-->Special Report</a> <span class="mlt-article-site-label"><!--?lit$067074646$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$067074646$-->Jul 08, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMsr2105280?query=recirc_Semantic" target="_self">SARS-CoV-2 Variants and Vaccines</a></div><div class="mlt-article-authors"><!--?lit$067074646$-->P.R. Krause and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$067074646$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$067074646$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$067074646$-->May 12, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2201821?query=recirc_Semantic" target="_self">Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers</a></div><div class="mlt-article-authors"><!--?lit$067074646$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$067074646$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$067074646$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$067074646$-->Jul 08, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2107808?query=recirc_Semantic" target="_self">Vaccine Breakthrough Infections with SARS-CoV-2 Variants</a></div><div class="mlt-article-authors"><!--?lit$067074646$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$067074646$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$067074646$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$067074646$-->May 13, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2100362?query=recirc_Semantic" target="_self">New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications</a></div><div class="mlt-article-authors"><!--?lit$067074646$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2202261?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2202261" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2202261.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2202261"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2201300" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2119662" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f1.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/afe6bc88-4dd6-402a-bd8c-2c2b4c01a8d6/assets/images/large/nejmoa2202261_f1.jpg" height="2990" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, Follow-up, and Analyses Performed up to the Second Data Cutoff Date of December 15, 2021.</div><div class="notes"><div role="doc-footnote">Eight participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group in the safety analysis. Covid-19 denotes coronavirus disease 2019.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f2.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/60565818-8d32-42d9-970e-ad174ee0ba13/assets/images/large/nejmoa2202261_f2.jpg" height="1932" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Plots of the Cumulative Incidence of Symptomatic Covid-19 in the Trial Groups.</div><div class="notes"><div role="doc-footnote">The cumulative incidence of symptomatic Covid-19, as confirmed on real-time polymerase-chain-reaction (PCR) assay, with an onset of at least 7 days after the third dose of ZF2001 or placebo (the primary end point) in the modified full analysis set for efficacy is shown at the first data cutoff date of June 30, 2021 (Panel A) and at the second data cutoff date of December 15, 2021 (Panel B). The cumulative incidence of real-time PCR–confirmed symptomatic Covid-19, with an onset after the first dose of ZF2001 or placebo, in the full analysis set for efficacy is shown at the first data cutoff date of June 30, 2021 (Panel C) and at the second data cutoff date of December 15, 2021 (Panel D). In each panel, the inset shows the same data on an enlarged y axis.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202261_f3.jpg"><img src="/cms/10.1056/NEJMoa2202261/asset/7120cef1-8a66-4a6d-bc0f-d9322de9b038/assets/images/large/nejmoa2202261_f3.jpg" height="2664" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events at the Second Data Cutoff Date of December 15, 2021.</div><div class="notes"><div role="doc-footnote">Panel A shows the incidence of adverse events, both overall and according to age group, among the participants who received at least one dose of ZF2001 or placebo. Panel B shows the overall incidence of local and systemic adverse reactions. A total of 28,873 participants were included in the safety analysis set (14,448 in the ZF2001 group and 14,425 in the placebo group); 8 participants who had been randomly assigned to receive placebo and instead received at least one dose of ZF2001 (protocol violation) were included in the ZF2001 group for the safety analysis.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Intention-to-Treat Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Vaccine Efficacy of ZF2001 against Covid-19 According to Analysis Groups.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/22" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 22</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 02, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2203163" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A. Papi and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 02, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2119662" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R. Leidner and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 02, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2201153" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.S. Levey, M.E. Grams, and L.A. Inker</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2202261%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2202261&amp;pubId=41283775&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2202261%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2202261&amp;pubId=41283775&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6d4f893d13289-SJC"></script><a role="link" id="icon-id060321766606359" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6d4f893d13289-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6d4f893d13289-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6d4f893d13289-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6d4f893d13289-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6d4f893d13289-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6d4f893d13289-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6d4f893d13289-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6d4f893d13289-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6d4f893d13289-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6d4f88b1b3289',t:'MTc0OTUzNzE1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6d4f88b1b3289&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><tjh-mktxuturqjmp></tjh-mktxuturqjmp><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2202261?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-transactionid="hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" id="captureIFrame_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" target="captureIFrame_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="capture_screen"><input id="capture_signIn_js_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="js_version"><input id="capture_signIn_transactionId_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" type="hidden" class="capture_transactionId_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="capture_transactionId"><input id="capture_signIn_form_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="form"><input id="capture_signIn_flow_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="flow"><input id="capture_signIn_client_id_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="client_id"><input id="capture_signIn_redirect_uri_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="redirect_uri"><input id="capture_signIn_response_type_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="response_type"><input id="capture_signIn_flow_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="flow_version"><input id="capture_signIn_settings_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="settings_version"><input id="capture_signIn_locale_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="locale"><input id="capture_signIn_recaptcha_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_hysjlh4f1sdfhkzroyiqefxf3kx2v1zoqgcs6qrs" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>